

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5: C07K 13/00, 15/28, C12N 1/21, 5/10, 15/10, 15/11, 15/19, 15/64, C12Q 1/00		A1	(11) International Publication Number: WO 94/15964 (43) International Publication Date: 21 July 1994 (21.07.94)												
(21) International Application Number: PCT/US94/00545 (22) International Filing Date: 18 January 1994 (18.01.94) (30) Priority Data: <table> <tr> <td>08/006,067</td> <td>15 January 1993 (15.01.93)</td> <td>US</td> </tr> <tr> <td>08/017,052</td> <td>11 February 1993 (11.02.93)</td> <td>US</td> </tr> <tr> <td>08/145,006</td> <td>29 October 1993 (29.10.93)</td> <td>US</td> </tr> </table>		08/006,067	15 January 1993 (15.01.93)	US	08/017,052	11 February 1993 (11.02.93)	US	08/145,006	29 October 1993 (29.10.93)	US	<p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): RAO, Anjana [US/US]; 19 Agassiz Street, Cambridge, MA 02140 (US). HOGAN, Patrick, Gerald [US/US]; 19 Agassiz Street, Cambridge, MA 02140 (US). McCAFFREY, Patricia [US/US]; 35 Ware Road, Newton, MA 02166 (US). JAIN, Jugnu [GB/US]; 21 Eisenhower Avenue, Natick, MA 01760 (US).</p> <p>(74) Agent: FRASER, Janis, K.; Fish & Richardson, 225 Franklin Street, Boston, MA 02110-2804 (US).</p> <p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>				
08/006,067	15 January 1993 (15.01.93)	US													
08/017,052	11 February 1993 (11.02.93)	US													
08/145,006	29 October 1993 (29.10.93)	US													
<p>(60) Parent Applications or Grants (63) Related by Continuation</p> <table> <tr> <td>US</td> <td>08/145,006 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>29 October 1993 (29.10.93)</td> </tr> <tr> <td>US</td> <td>08/017,052 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>11 February 1993 (11.02.93)</td> </tr> <tr> <td>US</td> <td>08/006,067 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>15 January 1993 (15.01.93)</td> </tr> </table> <p>(71) Applicants (<i>for all designated States except US</i>): DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 44 Binney Street, Boston, MA 02115 (US). PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02139 (US).</p>				US	08/145,006 (CIP)	Filed on	29 October 1993 (29.10.93)	US	08/017,052 (CIP)	Filed on	11 February 1993 (11.02.93)	US	08/006,067 (CIP)	Filed on	15 January 1993 (15.01.93)
US	08/145,006 (CIP)														
Filed on	29 October 1993 (29.10.93)														
US	08/017,052 (CIP)														
Filed on	11 February 1993 (11.02.93)														
US	08/006,067 (CIP)														
Filed on	15 January 1993 (15.01.93)														
<p>(54) Title: NF-AT_p, A T LYMPHOCYTE DNA-BINDING PROTEIN</p> <p>(57) Abstract</p> <p>An isolated NF-AT_p protein, a T lymphocyte DNA binding protein, is described. Isolated nucleic acids encoding the protein are also disclosed, as are methods for producing the protein by recombinant means. Methods for screening potential immunosuppressant compounds, which interfere with or inhibit lymphokine gene activation through the NF-AT pathway, are described. Such methods detect phosphorylation of the NF-AT protein.</p>															

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BV	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

NF-AT_p, A T LYMPHOCYTE DNA-BINDING PROTEIN

Field of the Invention

The invention relates to immunosuppressant
5 compounds.

Background of the Invention

The nuclear factor of activated T cells (NF-AT) is an inducible, lymphoid-specific transcription factor that is essential for expression of the IL-2 gene upon T cell 10 activation (For a review, see Ullman, K.S., Northrop, J.P., Verweij, C.L., Crabtree, G.R. (1990) *Ann. Rev. Immunol.* 8, 421-452). By cell fractionation and reconstitution experiments, NF-AT was shown to be assembled in the nucleus of activated T cells from a T 15 cell-specific component that is preexisting before activation and an inducible nuclear component (Flanagan, W.M., Corthesy, B., Bram, R.J., and Crabtree, G.R. (1991) *Nature* 352, 803-807). The preexisting component of NF-AT (here designated NF-AT_p) was subsequently identified in 20 hypotonic extracts of unstimulated T cells by its ability to bind specifically to an oligonucleotide corresponding to the distal NF-AT sequence from the murine IL-2 gene promoter (Jain, J., McCaffrey, P.G., Valge-Archer, V.E., and Rao, A. (1992) *Nature* 356, 801-804). In addition, it 25 was shown that the inducible nuclear component of NF-AT consists of Fos and Jun proteins, (Jain et al., *supra*).

- 2 -

Assembly of NF-AT in the nucleus requires two intracellular signals, the activation of protein kinase C and an increase in cytosolic free calcium, both of which are provided by activation of T cells through the T cell antigen receptor. Activation of protein kinase C is necessary for transcriptional induction of Fos and Jun genes (Jain, J., Valge-Archer, V.E., and Rao, A. (1992) *J. Immunol.* **148**, 1240-1250). An increase in intracellular calcium is necessary for the appearance of NF-AT_p in the nucleus, presumably reflecting its translocation from the cytosol (Flanagan, W.M., Corthesy, B., Bram, R.J., and Crabtree, G.R. (1991) *Nature* **352**, 803-807). The immunosuppressive drugs cyclosporin A (CsA) and FK506 block induction of NF-AT by interfering with the calcium-dependent appearance of NF-AT_p in the nucleus. CsA and FK506, when complexed with their specific intracellular binding proteins (cyclophilin and FK506 binding protein, respectively), potently inhibit the activity of the calcium- and calmodulin-dependent phosphatase, calcineurin (Klee, C.B., Draetta, G.F., Hubbard, M.J. (1987) *Adv. Enz.* **61**, 149-200); Fruman, D.A., Klee, C.B., Bierer, B.E., Burakoff, S.J. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 3686-3690), towards peptide substrates (Liu, J., Farmer, J.D., Jr., Lane, W.S., Friedman, J., Weissman, I., and Schreiber, S.L. (1991) *Cell* **66**, 807-815). Based on these results, it has been proposed that NF-AT_p in the cytosol may be a target for calcineurin, either directly as a substrate or indirectly via a phosphatase cascade (Schreiber, S.L., and Crabtree, G.R. (1992) *Immunology Today* **13**, 136-142).

Summary of the Invention

In accordance with the present invention, we have demonstrated that the DNA-binding component of the NF-AT T cell nuclear factor, herein referred to as NF-AT_p, is a 35 90-140 kDa T cell phosphoprotein that binds directly and

- 3 -

specifically to the NF-AT sequence and that calcineurin can cause dephosphorylation of this protein in T cell lysates. These findings directly implicate NF-AT_p in the chain of events by which CsA and FK506 inhibit IL-2 gene induction.

As described in detail below, NF-AT_p is present in resting T cells predominantly in a form migrating with an apparent molecular weight of 110-140 kDa, while NF-AT_p from nuclear extracts of activated T cells migrates with a lower apparent molecular weight (90-125 kDa). This difference reflects dephosphorylation of NF-AT_p, since treatment of NF-AT_p with calf intestinal phosphatase or the calcium- and calmodulin-dependent phosphatase calcineurin *in vitro* results in a similar decrease in its apparent molecular weight. We show that NF-AT_p is dephosphorylated in cell lysates by a calcium-dependent process that is blocked by inclusion of EGTA or a specific peptide inhibitor of calcineurin in the cell lysis buffer. Moreover, dephosphorylation of NF-AT_p in cell extracts is inhibited by prior treatment of T cells with the immunosuppressive drugs cyclosporin A (CsA) or FK506, which inhibit the phosphatase activity of calcineurin when complexed with their specific binding proteins, cyclophilin and FK506 binding protein. This work identifies NF-AT_p as a DNA-binding phosphoprotein and a target for drug/immunophilin/calcineurin complexes thought to mediate the inhibition of IL-2 gene induction by CsA and FK506.

In one embodiment, the invention provides a purified preparation of NF-AT_p protein, preferably a human NF-AT_p protein. The protein can be phosphorylated, or not phosphorylated. In accordance with the invention, purified preparations of NF-AT_p protein can be complexed with a Fos protein, a Jun protein, or with both a Fos and a Jun protein to form a complex resembling the native

- 4 -

nuclear factor of activated T cells (NF-AT), which can be used to screen for regulatory sequences in the promoter regions of other cytokine genes or genes of other immune regulatory proteins for binding to the complexes. Such 5 genes encode proteins that may constitute a family whose transcription is regulated by a similar mechanism and provide the basis of drug design strategies to manipulate the immune response.

In another embodiment of the invention, there is 10 provided an isolated DNA encoding NF-AT_p. The DNA preferably encodes a mammalian NF-AT_p protein or functional fragment, derivative, or isoform thereof, and most preferably encodes a human or a murine NF-AT_p protein. The isolated DNA may encode a protein which 15 contains the amino acid sequence of murine NF-AT_p (SEQ ID NO:5) or human NF-AT_p (SEQ ID NO:12). The invention also includes isolated DNA containing part or all of either the sequence of murine NF-AT_p shown in Fig. 22 (SEQ ID NO:21) or human NF-AT_p shown in Fig. 17 (SEQ ID NO:11), 20 Fig. 21 (SEQ ID NO:19) or Fig. 23 (SEQ ID NO:20). Also provided are vectors containing the isolated DNA; cells, which can be prokaryotic or eukaryotic, containing the isolated DNA; and methods of manufacturing NF-AT_p. The methods comprise culturing the cells containing NF-AT_p, 25 under conditions permitting expression of the DNA.

In yet another embodiment of the invention, there are provided antibodies or fragments or variants thereof that bind to an epitope of the NF-AT_p protein. The antibodies can be polyclonal or monoclonal, and can 30 recognize an epitope of the NF-AT_p protein in a denatured or native form. The antibodies, especially the antibodies that bind to an epitope of native NF-AT_p protein, are particularly useful in detecting expression of NF-AT_p in a cell. Expression of the NF-AT_p protein can 35 be detected by contacting a mixture of proteins from the

- 5 -

cells of interest with an anti-NF-AT_p antibody of the invention, which is labeled, and detecting immune complex formation.

Expression of the NF-AT_p protein in a cell can 5 also be detected by contacting mRNA obtained from the cell with a labeled hybridization probe comprising, for example, a single-stranded segment of isolated DNA encoding a fragment of the NF-AT_p protein and detecting hybridization of the probe with the mRNA. The invention 10 includes an isolated DNA containing 20 nucleotides that hybridizes under stringent conditions to a strand of a DNA encoding NF-AT_p. By the term "stringent conditions" is meant DNA hybridization and wash conditions characterized by relatively high temperature and low salt 15 concentration, e.g., conditions described in Sambrook et al., (1989) *Molecular Cloning: a Laboratory Manual*, second edition., Cold Spring Harbor Press, Cold Spring Harbor, N.Y), page 7.52 of which is herein incorporated by reference. The segment of DNA may be 20 nucleotides, 20 preferably 50 nucleotides, more preferably 100 nucleotides, and most preferably 200 nucleotides in length.

In yet another embodiment, the invention includes an isolated DNA which encodes a segment of NF-AT_p which 25 binds to Fos-Jun or Jun-Jun, e.g., nucleotides 672-2063 of SEQ ID:21. By "Fos-Jun" is meant the heterodimeric complex of the transcription factors Fos and Jun. By "Jun-Jun" is meant the homodimeric complex of the transcription factor, Jun.

30 Other embodiments of the invention are directed to methods for screening for potential immunosuppressant compounds, which interfere with or inhibit lymphokine gene activation through the NF-AT pathway. One such method takes advantage of our discovery that the NF-AT_p 35 exists in a phosphorylated form in inactivated T cells,

- 6 -

but is dephosphorylated via a phosphatase after activation through the T cell receptor. This method involves providing purified, phosphorylated NF-AT_p protein; contacting the NF-AT_p protein with a 5 phosphatase, such as calcineurin or calf intestinal phosphatase, in the presence of a candidate immunosuppressive compound; and determining whether dephosphorylation of NF-AT_p by the phosphatase is inhibited by the candidate compound.

10 Another method for screening potential immunosuppressive agents in accordance with the present invention comprises providing purified NF-AT_p; contacting the purified NF-AT_p, in the presence of a candidate immunosuppressive compound, with an 15 oligonucleotide comprising a sequence substantially identical to a 5' NF-AT DNA sequence which binds the NF-AT_p component of the NF-AT complex and determining whether the candidate compound inhibits binding of the oligonucleotide to NF-AT_p. In a preferred embodiment, 20 the oligonucleotide is GCCCAAAGAGGAAAATTTGTTTCATACAG (SEQ ID NO:1).

Yet another method for screening potential immunosuppressive agents in accordance with the present invention involves providing purified NF-AT_p; contacting 25 the NF-AT_p with a Fos protein in the presence of a candidate immunosuppressive compound; and determining whether the candidate compound inhibits binding of the Fos protein to the NF-AT_p protein. The same method can alternatively be used with a Jun protein or a combination 30 of Fos and Jun proteins, and involves providing purified NF-AT_p; contacting the NF-AT_p with Jun or a combination of Fos and Jun in the presence of a candidate immunosuppressive compound; and determining whether the candidate compound 35 inhibits binding of the proteins to the NF-AT_p protein.

- 7 -

Other aspects of the invention will be appreciated by persons skilled in the art from the specification and claims herein.

Brief Description of the Drawing

- 5 Fig. 1 is a series of photographs of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels showing the identification of T cell-specific NF-AT-binding proteins by renaturation of denatured protein separated and purified from SDS-PAGE
- 10 gels. The top portion of the figure is a silver stain of an analytical 10% SDS-PAGE gel after fractionation of hypotonic extracts (4 µg total protein) from the murine T cell clone Ar-5 or a murine fibroblast cell line (L cells). The migration of standards and their molecular
- 15 weights in kDa are indicated above. The bottom portions of the figure illustrate DNA-binding activity of proteins eluted and renatured from a preparative SDS-polyacrylamide gel, and assayed by electrophoretic mobility shift assay (EMSA) using an NF-AT
- 20 oligonucleotide corresponding to the distal NF-AT site from the murine IL-2 promoter. Lanes 1-18 represent proteins eluted from successive 0.5 cm slices of a preparative SDS gel which was loaded with 200 µg total protein from the same extracts shown on the silver
- 25 stained analytical gel. The arrow indicates the mobility of a protein-DNA complex detected in T cell extracts but not in L cell extracts. Lanes 6 and 7 contain proteins of apparent molecular weight 107-120 kDa and 93-107 kDa, respectively.
- 30 Figs. 2A and 2B are photographs of SDS-PAGE gels in which NF-AT-binding proteins were detected in T cell nuclear extracts after renaturation from SDS-polyacrylamide gels. In Fig. 2A, Ar-5 cells were untreated (M), or treated for 2 hours with cross-linked

- 8 -

anti-CD3 ϵ antibody (α CD3), 1 μ M CsA, or both anti-CD3 ϵ and CsA as indicated. Nuclear extracts were prepared and 200 μ g of total protein was fractionated by SDS-PAGE, followed by elution and renaturation of proteins as in
5 Fig. 1. The binding of proteins from three consecutive gel slices (representing the molecular weight ranges 122-144, 102-122, and 86-102 kDa as indicated) to the NF-AT oligonucleotide is shown. In Fig. 1B, specificity of binding of the renatured proteins to the NF-AT
10 oligonucleotide. Renatured NF-AT-binding proteins from hypotonic extracts (left panel) or nuclear extracts (right panel) were assayed for binding to the NF-AT oligonucleotide in the presence of a 200-fold excess of unlabeled NF-AT oligonucleotide (here labeled NF-AT-1,
15 lane 2), or oligonucleotides bearing mutations in the NF-AT sequence (M1, M2, M3, lanes 3-5).

Fig. 3 is a photograph of an EMSA gel showing that NF-AT-binding proteins derived from V8 protease treatment of hypotonic or nuclear extracts are similar to those
20 derived from NF-AT_p renatured from SDS-acrylamide gels. Hypotonic extract, nuclear extract, or NF-AT-binding protein renatured from hypotonic extract, were mixed with increasing amounts of V8 protease as indicated, followed by addition of binding buffer, dI:dC, and labelled NF-AT
25 oligonucleotide for the EMSA. The mixtures were incubated for 15 minutes at room temperature, and then subjected to gel electrophoresis at 4°C. Because the gel was run at 4°C, a more slowly migrating nuclear form of NF-AT (composed of NF-AT_p plus Fos and Jun proteins) is
30 faint in this gel (lane 5), but the same results are obtained when electrophoresis is done room temperature where the larger complex is more apparent.

Figs. 4A and 4B are photographs of an EMSA gel showing the effect of treatment of NF-AT_p with exogenous
35 phosphatases. A shift in NF-AT_p mobility was observed on

- 9 -

polyacrylamide gels. NP-40 extracts of Ar-5 cells were ammonium sulfate precipitated to enrich NF-AT_p proteins, and the resulting proteins were treated with calf intestinal phosphatase (CIP) (Fig. 4A) or calcineurin 5 (CaN) (Fig. 4B) as detailed below. The proteins were then fractionated on SDS-PAGE gels, eluted from individual gel slices spanning the molecular weight ranges indicated, renatured and assayed for binding to the NF-AT oligonucleotide. The solid arrow denotes NF- 10 AT_p, while the open arrow denotes a minor complex appearing in the slice containing proteins of molecular weight 127-143 kDa.

Figs. 5A through 5C are photographs of EMSA gels showing that NF-AT_p is a target for CsA. Hypotonic 15 extracts (250 µg total protein) from untreated Ar-5 cells (Fig. 5A) or cells treated for 10 minutes with 1 µM CsA (Fig. 5B) were fractionated on SDS-acrylamide gels. Proteins were eluted and renatured from individual gel slices, and assayed for binding to the NF-AT 20 oligonucleotide. In Fig. 5C, equal amounts of extracts (125 µg protein each) from untreated or CsA-treated cells were mixed after boiling in SDS-PAGE sample buffer and fractionated as for Figs. 5A and 5B. In each of Figs. 5A through 5C, the solid arrow denotes NF-AT_p, while the 25 open arrow denotes a minor complex appearing in slice 3 (see text for discussion).

Fig. 6 is a photograph of a portion of an EMSA gel showing the results of an EMSA. The effect of a calcineurin inhibitor peptide on the mobility of NF-AT_p 30 is shown. Ar-5 cells were lysed by freeze-thawing in hypotonic buffer containing 100 µM of either a specific calcineurin inhibitory peptide (IC₅₀, 10 µM), or a control peptide containing a single amino acid substitution that does not inhibit calcineurin (IC₅₀ >200 µM). The extracts 35 (200 µg protein) were fractionated on SDS-acrylamide

- 10 -

gels, and proteins were renatured from gel slices spanning the molecular weight ranges indicated (corresponding to lanes 3, 4 and 5 in Figs. 5A-5C), and assayed for NF-AT binding. Only the portion of the gel 5 shift gel containing the NF-AT_p-DNA complexes is shown.

Fig. 7 is a photograph of an EMSA gel showing the results of an EMSA. Purified NF-AT_p was shown to associate in vitro with recombinant Fos and Jun proteins. Partially purified NF-AT_p was incubated with labeled 10 oligonucleotide corresponding to the distal NF-AT site of the murine IL-2 promoter, either alone (lanes 1, 7, 13), with full length or truncated (T) recombinantly produced c-Fos and c-Jun proteins (lanes 2-5 and 8-11, respectively) or with an equivalent concentration of 15 bovine serum albumin. Lane 5 contained 50% more c-Fos and c-Jun compared to lane 4. Lanes 11-13 contain half the amount of NF-AT_p compared to lanes 1-10. Lane 14 shows a binding reaction of nuclear extracts from stimulated AR-5 T cells. Bound complexes were separated 20 from free probe by EMSA. The position of free probe, of the lower (NF-AT_p) complex and upper (NF-AT_p-Fos-Jun) complex are indicated.

Fig. 8 is a photograph of an EMSA gel showing an analysis of NF-AT_p by renaturation of NF-AT_p activity 25 following purification of the protein using SDS-polyacrylamide gel electrophoresis. In the top panel, purified NF-AT_p (50 ng) was subjected to electrophoresis on an analytical 6% SDS-PAGE gel and subsequently silver-stained (Pierce Gel-code kit). In the bottom panel, a 30 second lane of the same gel was loaded with 50 ng of the purified protein. After electrophoresis, the gel was sliced, proteins were eluted from gel slices and renatured, and the fractionated proteins were evaluated in an EMSA for their ability to bind to the NF-AT site of 35 the murine IL-2 promoter.

- 11 -

Fig. 9 is a photograph of an EMSA gel showing the results of an EMSA. Antisera to tryptic peptides of purified NF-AT_p recognize NF-AT_p in T cell extracts. Cytosolic extracts from unstimulated Ar-5 T cells (lanes 1-5) or nuclear extracts from Ar-5 T cells stimulated with anti-CD3 (lanes 6-10) were incubated without antiserum (lanes 1 and 6), with antiserum to peptide 72 (residues 206-227 of SEQ ID NO:5, see Fig. 10) (immune, lanes 3 and 8) or with serum from the same rabbit taken before immunization (preimmune, lanes 2 and 7), then analyzed by EMSA for binding to the NF-AT oligonucleotide. For peptide competition, 1 mg of peptide 72 (lanes 4 and 9) or peptide 25 (residues 685-703 of SEQ ID NO:5, see Fig. 10) (lanes 5 and 10) was mixed with the antiserum before it was added to cell extracts. Filled arrowheads identify the cytosolic NF-AT_p, nuclear NF-AT_p, and nuclear NF-AT_p/Fos/Jun complexes; open arrowheads indicate the "supershifted" complexes; the unmarked complex results from binding of serum proteins.

Fig. 10 is a diagram of the deduced amino acid sequence of murine NF-AT_p (SEQ ID NO:5) in which the sequences of tryptic peptides from purified NF-AT_p are underlined. "X" in the underlining for peptides 23.3 and 72 indicate positions at which the identity of the amino acid could not be determined unambiguously. The sequence between the arrowheads represents the NF-AT_p sequence contained within the recombinant protein that was expressed in bacteria.

Fig. 11 is an autoradiograph of a Northern blot analysis of NF-AT_p mRNA from T cell and fibroblast cell lines. Cytoplasmic RNA from the murine T cell clone Ar-5, the transformed T cell line Cl.7W2, and the murine fibroblast L cell line were separated by electrophoresis in formaldehyde gels, transferred to nylon membranes and

- 12 -

- hybridized with a labelled fragment of NF-AT_p coding sequence corresponding to the approximately 800-bp PCR product. The positions of the major NF-AT_p transcript (arrow) and of 28S and 18S ribosomal RNAs are indicated.
- 5 The lower panel shows ethidium bromide staining of the RNA before transfer to nitrocellulose, indicating that the RNA was intact and that equivalent amounts of RNA were loaded in each lane.

Fig. 12 is a photograph of an EMSA gel. Binding 10 of a recombinant fragment of NF-AT_p (NF-AT_pXS) to target DNA and association of the recombinant NF-AT_p fragment with Fos and Jun proteins was evaluated. The binding of 15 the recombinant fragment of murine NF-AT_p to the distal NF-AT site of the murine IL-2 promoter was assessed by EMSA in the presence or absence of a 200-fold excess of 20 unlabelled competitor oligonucleotides as shown in Lane 1-5. The arrows indicate two DNA-protein complexes formed with NF-AT_pXS. Full-length recombinant c-Fos and c-Jun proteins were included in the same binding reactions, as shown in Lanes 7-9. The open arrows indicate Jun-Jun-NF-AT_pXS complexes, while the closed arrows indicate Fos-Jun-NF-AT_pXS complexes. Fos and Jun proteins do not bind to the NF-AT oligonucleotide, as shown in Lane 10.

25 Fig. 13 is a photograph of an EMSA gel showing the results of an EMSA. Antisera to recombinant NF-AT_p recognize NF-AT_p in T cell extracts. Cytosolic extracts from unstimulated Ar-5 T cells or nuclear extracts from 30 cells stimulated with anti-CD3 were incubated without antiserum (lanes 1 and 5), with an antiserum raised against the recombinant NF-AT_p fragment (lanes 3 and 7), or with preimmune serum from the same rabbit (lanes 2 and 6), followed by gel shift analysis of binding to the NF-AT oligonucleotide.

- 13 -

Fig. 14 is a photograph of RNA transcripts resolved on denaturing polyacrylamide gels and quantitated using a phosphorimager. Transcriptional activation by NF-AT_p, c-Fos and c-Jun on different 5 templates was analyzed. The templates indicated above the lanes were incubated with the proteins listed and transcribed *in vitro* in nuclear extracts from Namalwa cells. The template pMILNFAT-CAT (lanes 1-14) contains three NF-AT sites upstream of the basal IL-2 promoter; 10 the template pMILM3-CAT (lanes 15-17) contains four NF-AT sites in which critical contact residues have been altered; and the template pCOL-CAT contains residues -73 to +63 of the human collagenase promoter including an AP-1 site. The filled arrowheads point to the specific 15 transcripts and the open arrowheads to internal controls. The level of transcription in the presence of different combinations of proteins was expressed relative to a reaction in the absence of recombinant proteins (fold activation). The average of several independent 20 experiments (number shown at the base of each bar) and the standard deviation in cases in which more than three independent experiments were performed are shown (solid bars: activation; open bars: repression).

Fig. 15 is an autoradiograph of a Southern 25 hybridization assay. A labelled probe made from the EcoRI fragment (described in text) of the murine NF-AT_p cDNA, representing the 5' end of coding sequence contained in clone mNF-AT_p-Q1B1/A, hybridizes to specific restriction fragments of human genomic DNA. 30 Hybridization of the same probe to restriction fragments of murine genomic DNA is shown for comparison.

Fig. 16 is an autoradiograph of a Southern 35 hybridization assay. A labelled probe made from the SphI-3' fragment (described in text) of the murine NF-AT_p cDNA, representing the 3' end of coding sequence common

- 14 -

to all alternatively spliced forms of murine NF-AT_p, hybridizes to specific restriction fragments of human genomic DNA. Hybridization of the same probe to restriction fragments of murine genomic DNA is also
5 shown.

Fig. 17 is a representation of a partial cDNA sequence of human NF-AT_p (SEQ ID NO:11).

Fig. 18 is a representation of the amino acid sequence deduced from the partial cDNA sequence of human
10 NF-AT_p (SEQ ID NO:12).

Fig. 19 is a diagram showing the comparison of the murine and human cDNA sequences in the region of overlap encoding NF-AT_p (SEQ ID NO:8 and SEQ ID NO:22, respectively).

15 Fig. 20 is a diagram showing murine isoforms of NF-AT_p. Sequences shown are (1) nucleotides 2201-2260 of mNF-AT_p-Q1B1/A sequence, (2) splicing variant mNF-AT_p-R3B1, and (3) splicing variant mNF-AT_p-T2B1. The alternatively spliced forms are identical in sequence to mNF-AT_p-Q1B1/A
20 in the region up to and including nucleotide 2208 of mNF-AT_p-Q1B1/A, shown in lower case letters. While the coding sequence of mNF-AT_p-Q1B1/A continues 3' to the 60-nucleotide region shown, both variant forms have in-frame stop codons, shown in boldface type.

25 Fig. 21 is a DNA sequence (SEQ ID NO:19) of the NF-AT_p gene.

Fig. 22 is a partial cDNA sequence of murine and NF-AT_p (SEQ ID NO:21) (GenBank U02079) from the plasmid mNFATp-Q1B1/A. The plasmid mNFATp-Q1B1/A also contains
30 ~150 nucleotides of 3'-untranslated region after the stop codon.

Fig. 23 is a partial cDNA sequence from the human NF-AT_p gene (SEQ ID NO:20).

- 15 -

Detailed Description

Purification of NF-AT_p

In one embodiment, the invention features a purified preparation of NF-AT_p protein, which NF-AT_p may 5 be human, murine, bovine, or any other mammalian NF-AT_p, and which may be prepared, for example, from a natural source, from an expression system expressing an isolated DNA encoding NF-AT_p, or by synthetic means well known to persons skilled in the art. For example, the protein can 10 be fractionated on a gel by SDS-PAGE, recovered, and then renatured, as described in the Examples.

A preferred method for purifying the NF-AT_p involves lysing T cells that are rich sources of NF-AT_p protein, precipitating the protein from cell lysates 15 using a salt, such as ammonium sulfate, and purifying the NF-AT_p protein on heparin-agarose and then on an affinity column.

The mouse T cell line C1.7W2 (Valge-Archer et al., *J. Immunol.*, 145:4355 (1990) has been found to be a rich 20 source of NF-AT_p protein, which can be used in the purification methods of the invention. Hypotonic extracts of the cells are prepared from these cells by lysing about 2.5×10^7 cells/ml in a buffer containing 10 mM Tris (pH 8.0), 50 mM NaCl, 0.05% NP-40, 1 mM EDTA, 100 25 μ g/ml aprotinin, 25 μ M leupeptin, 2 mM PMSF, 10 mM iodoacetamide (IAM). The resulting extracts are centrifuged at low speed to remove the nuclei, then at 100,000 X g for one hour.

After centrifugation, the protein mixture is salt 30 precipitated with an equal volume of appropriate reagent, which is preferably ammonium sulfate (final 1.5 M) and the precipitate resuspended in one-tenth volume relative to cell lysate of buffer, for example buffer A (20 mM Hepes, pH 7.4, 100 mM NaCl, 2 mM EDTA, 10% glycerol)

- 16 -

containing 100 µg aprotinin, 25 µg leupeptin, 2 mM PMSF, and 10 mM IAM. The lysate is dialyzed versus the buffer A with 0.5 mM DTT.

The dialyzed extract is further purified by 5 fractionation on heparin-agarose, in accordance with standard procedures. For example, a salt, such as NaCl, is added to the final concentration of lysate and the batch adsorbed onto heparin-agarose. The column is then loaded, washed with buffer (e.g. buffer A containing 0.2 10 M NaCl) and the proteins eluted with salt gradients of 0.2 to 1 M of reagent. Active fractions are pooled and dialyzed versus buffer. The recoveries at this step are typically 25 to 40%.

The material eluted from the heparin-agarose 15 column is then subjected to two or three rounds of affinity purification using NF-AT oligonucleotides from the promoter region of a mammalian IL-2 gene. A sepharose column conjugated with about 100-200 nM multimerized murine NF-AT oligonucleotides, e.g. as in 20 SEQ ID NO:1 per ml of resin can be used. In a typical purification, after two rounds of affinity chromatography, the specific activity of the NF-AT_p preparation is about 160,000 U/mg of protein, indicating that about 2% of the protein recovered from the column 25 was NF-AT_p.

Higher capacity columns for affinity purification can also be used, in which higher concentrations of NF-AT oligonucleotides are conjugated to the sepharose column. A high capacity column for affinity purification of 30 sequence-specific DNA binding proteins that can be used in accordance with the invention is described in Larson and Verdine, Nucleic Acids Research, 20:3525 (1992). This column is used in the presence of herring sperm DNA.

The purified protein can be phosphorylated or 35 unphosphorylated, and can be detected on a gel based upon

- 17 -

the molecular weights determined in accordance with the present invention. Thus, the phosphorylated form of native NF-AT_p exhibits a molecular weight about 110-140 kDa, while the dephosphorylated native protein exhibits a 5 molecular weight of about 100-120 kDa.

The invention also includes purified preparations of a complex of NF-AT_p with a Fos protein, a Jun protein, a combination of Fos plus Jun, or any other such protein with which NF-AT_p is naturally functionally associated in 10 vivo. It is contemplated that a number of members of the Fos and Jun protein families known to persons skilled in the art will bind NF-AT_p and can therefore be used to form the complexes of the invention. c-Fos and c-Jun proteins are particularly suitable. See, Jain et al., 15 (1992), *supra*. Other proteins that might be complexed with NF-AT_p include other leucine zipper proteins, such as C/EPBs and CREBs. Like Fos and Jun, these proteins are capable of forming homodimers and heterodimers with one another and therefore might associate with NF-AT_p in 20 the same manner as Fos and Jun proteins.

The multicomponent complexes can be used in vitro transcription assays in order to identify other genes under the control of a promoter which responds to the same or structurally similar complex. An in vitro 25 transcription assay that can be used in accordance with the invention is described, for example, in Kretzschmar et al., Genes and Development, 6:761-772 (1992), the pertinent portions of which are hereby incorporated by reference. The complexes are also useful in identifying 30 candidate immunosuppressants which exhibit the ability to inhibit formation or to cause dissociation of the two or three component complex.

- 18 -

Isolation of DNA clones for NF-AT_p and related proteins

Also within the invention are isolated DNAs which encode NF-AT_p. By "isolated DNA" is meant that the DNA molecule encodes NF-AT_p, but is free of the genes that, 5 in the naturally-occurring genome of the organism from which the DNA of the invention is derived, immediately flank the gene encoding NF-AT_p. The term therefore encompasses, for example, a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease 10 treatment, whether such cDNA or genomic DNA fragment is incorporated into a vector, integrated into the genome of the same or a different species than the organism from which it was originally derived, linked to an additional coding sequence to form a hybrid gene encoding a chimeric 15 polypeptide, or independent of any other DNA sequences.

The DNA may be double-stranded or single-stranded, sense or antisense. The isolated DNA of the invention may be under the transcriptional control of a heterologous promoter (i.e., a promoter other than one 20 naturally associated with the NF-AT_p gene), which promoter, for example, may direct the expression of the DNA of the invention in a particular tissue or at a particular stage of development. A cell which contains such isolated DNA may be cultured under conditions 25 permitting the expression of the DNA, providing a method for conveniently manufacturing recombinant NF-AT_p. Prokarytic or eukarotic cells can be used to express the protein encoded by the NF-AT_p gene, including bacteria such as E. coli, yeast, insect cells, and mammalian cells 30 such as CHO and COS cell lines well known to persons skilled in the art.

Fragments of the cDNA encoding NF-AT_p, e.g., fragments encoding functional domains, can be used to express protein to determine the 3-dimensional structure

- 19 -

of the NF-AT_p transcriptional regulatory complex. For example, the use of such fragments in competition assays may be useful in determining the regions of NF-AT_p contacted by the Fos and Jun proteins.

- 5 By the term "isoform" is meant the product of alternative splicing of the nucleic acid transcript encoding NF-AT_p.

Antibodies That Bind To NF-AT_p

- Purified NF-AT_p, or a peptide fragment thereof, 10 may be used to generate by standard methods a monoclonal or polyclonal antibody capable of binding to NF-AT_p. In one preferred embodiment, a monoclonal antibody is generated, using the purified NF-AT_p protein to immunize an appropriate laboratory animal, such as a mouse. The 15 mouse can be, for example, an RBF/DnJ hyperimmune mouse (Jackson Laboratories, Bar Harbor, ME). Three days after the final boost with protein, spleens are removed and spleen cells fused with NSI nonsecreting myeloma cells using standard protocols. Hybrid cells are selected by 20 growth in medium containing HAT or hypoxanthine and azaserine. Hybridoma cells secreting antibodies to NF-AT_p are identified by the ability of their culture supernatants to: (1) "supershift" or disrupt the NF-AT_p-DNA complex in a gel shift assay; and (2) stain the 25 approximately 120 kd NF-AT_p protein in a Western blot procedure. Hybrid cells the supernatants of which are positive in either assay are subcloned by limiting dilution, and used to produce ascites in (RBF/Dn x BALB /C) F1 mice.
- 30 In another preferred embodiment, polyclonal antisera are generated using NF-AT_p peptides as immunogens in rabbits. For generation of antisera against proteolytic fragments of NF-AT_p, rabbits were immunized with synthetic peptides. For example, to

- 20 -

generate peptide 72-specific antibodies, rabbits were immunized with a 21-amino-acid synthetic peptide contained within the amino acid sequence of peptide 72 conjugated to the carrier protein KLH.

5 The monoclonal antibodies generated by this procedure can be used to verify the identity of recombinant NF-AT_p cDNA clones obtained by expression or in vitro transcription/translation of the NF-AT_p cDNA clones. Polyclonal antisera can also be raised against 10 the expressed recombinant NF-AT_p protein. The antibodies are useful for determining the intracellular location of NF-AT_p: for example, by immunohistochemical staining of fixed and permeabilized T cells which are left unstimulated or are stimulated for 5 minutes to two hours 15 with anti-CD3 antibody.

Such antibodies, or fragments thereof, which bind to an epitope of NF-AT_p are also useful in a method for detecting expression of NF-AT_p in a cell or a tissue, which method includes the steps of contacting proteins of 20 the cell or tissue (e.g., using whole-cell lysates, proteins extracted from the cytoplasm or nucleus of the cell, or *in situ* on a tissue sample) with the antibody, and detecting immune complex formation using standard immunoassay techniques such as ELISA.

25 Likewise, a standard Northern blot assay employing a NF-AT_p cDNA hybridization probe [e.g. full-length, single-stranded cDNA or a cDNA fragment at least 20 nucleotides in length (preferably at least 50 and more preferably at least 100) from a portion of the cDNA which 30 is not homologous to any known cDNA sequence] can be used to ascertain the relative amount of NF-AT_p mRNA in a cell or a tissue, in accordance with conventional techniques.

Either method of determining NF-AT_p expression could be used to identify cells or tissues in which the

- 21 -

level of NF-AT_p expression was higher or lower than normal, and thus to diagnose certain disease conditions. For example, a rare form of inherited immune dysfunction has been attributed to a lack of functional NF-AT_p in the 5 T cells of the patient, while certain cancers and lymphomas are believed to involve overexpression of the NF-AT_p gene.

Screening Methods

The characteristics of purified NF-AT_p disclosed 10 herein form the basis for several different methods for screening potential immunosuppressive agents. As an initial screen for potential immunosuppressants, candidate compounds can take the form of commercially available proteins or peptides (which are available in 15 libraries from a variety of sources known and available to the skilled artisan), or organic or inorganic compounds, also available in libraries, that bind to the NF-AT_p protein in either its phosphorylated or unphosphorylated form. Candidate compounds that bind to 20 NF-AT_p (as determined, for example, in an EMSA) can then be used in a more detailed screen, as described hereinafter.

For example, a candidate compound can be screened 25 for its ability to inhibit dephosphorylation of NF-AT_p, which in turn should result in down regulation of the lymphokine gene and hence act as an immunosuppressant. Potential immunosuppressive agents which act by blocking the dephosphorylation of NF-AT_p can be identified using any suitable phosphatase that exhibits the ability to 30 dephosphorylate NF-AT_p, as described in the Examples herein. Preferred phosphatases include the calcium and calmodulin-dependent phosphatase calcineurin and other T cell phosphatases known to persons skilled in the art. The screen involves providing purified, phosphorylated

- 22 -

NF-AT_p; contacting the NF-AT_p with a T cell phosphatase, e.g., calcineurin, in the presence of a candidate immunosuppressive compound; and determining whether dephosphorylation of NF-AT_p by the phosphatase is inhibited by the candidate compound. Phosphorylation status of NF-AT_p can be assessed, for example, as described in Fruman et al., Proc. Natl. Acad. Sci., USA, 89:3686-3690 (May 1992), the pertinent portions of which are hereby incorporated by reference. See, especially 10 page 3687 of Fruman et al. Alternatively, phosphorylation status of NF-AT can be evaluated using SDS-PAGE, as described in the Examples.

In another screening assay, purified NF-AT_p is contacted, in the presence of the candidate 15 immunosuppressive compound, with an oligonucleotide containing a sequence substantially identical to a mammalian NF-AT nucleotide sequence, preferably a sequence including GCCCAAAGAGGAAAATTGTTTCATACAG (SEQ ID NO:1); and inhibition of binding of the oligonucleotide 20 to NF-AT_p by the candidate compound is ascertained, with an inhibition of binding being an indication that the candidate compound is a potential immunosuppressive agent.

Other screening assays in accordance with the 25 invention are designed to detect inhibition of binding of a Fos and/or Jun protein to NF-AT_p by a candidate immunosuppressive compound. Such assays can be conducted in the presence or absence of NF-AT DNA. For example, in a DNA-based assay, incubation of purified or partially 30 purified NF-AT_p with labeled murine NF-AT site (SEQ ID NO:1) yields a single DNA-protein complex (See Fig. 7, lanes 1, 7, and 13) corresponding in migration to a "lower" NF-AT_p complex (Fig. 7, lane 14). Inclusion of c-Fos and c-Jun proteins in the binding reaction mixture 35 results in the appearance of a second complex (Fig. 7,

- 23 -

lanes 4 and 5) whose migration is identical to that of the "upper" NF-AT_p/Fos/Jun nuclear complex (Fig. 7, lane 14). The complex is not observed when NF-AT_p is incubated with c-Fos (See Fig. 7, lanes 2,3). In accordance with a DNA-based screening method, candidate compounds are incubated with a binding mixture including purified or partially purified NF-AT_p, Fos, and Jun and complex formation is detected in accordance with the foregoing. Candidate compounds which inhibit the formation of a NF-AT_p/Fos/Jun complex can be detected by viewing migration pattern on the gel.

Assays for screening candidate immunosuppressants that inhibit the association of NF-AT_p with Fos and/or Jun proteins can also be non-DNA based. For example, detection of complex formation or inhibition of Fos and/or Jun protein binding can be accomplished by analyzing the mass of the complex formed in the presence or absence of a candidate compound using a sucrose gradient, in accordance with established techniques.

See, e.g. Current Protocols In Molecular Biology, F.M. Ausubel. Ed., § 5.3 (Greene Publishing Associates and Wiley Interscience, N.Y., 1989). Inhibition of binding of Fos and Jun proteins to NF-AT_p can also be demonstrated by immunoprecipitating the binding reaction mixture, including a candidate compound, with antibodies to NF-AT_p, Fos, or Jun and detecting the presence or absence of complex formation. Antibodies to NF-AT_p can be prepared as described; antibodies to Fos and Jun proteins are available commercially, and can also be readily prepared by persons skilled in art, using conventional techniques. Yet another method of identifying potential immunosuppressants from candidate compounds that inhibit or interfere with NF-AT complex formation involves protein cross-linking procedures known in the art. See, e.g. Diamond et al., Science, 249:1266.

- 24 -

In another embodiment, phosphorylation of purified NF-AT_p by its naturally-occurring kinase may form the basis for an assay, with a compound that inhibits such phosphorylation having potentially significant effects on 5 the activity of a T cell.

Other features and advantages of the invention will be apparent from the following Examples.

In the Examples and specification, the following abbreviations are used and have the meanings 10 hereinafter identified: BSA, bovine serum albumin; CIP, calf intestinal phosphatase; CsA, cyclosporin A; DTT, dithiothreitol; EGTA, [ethylenebis(oxyethylenenitrilo)]-tetraacetic acid; Hepes, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; IL-2, interleukin-2; kDa, 15 kilodalton; NF-AT, nuclear factor of activated T cells; NF-AT_p, preexisting subunit of the nuclear factor of activated T cells; NP-40, Nonidet P-40, PMSF, phenylmethylsulfonyl fluoride; SDS, sodium dodecyl sulfate; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide 20 gel electrophoresis.

METHODS

Cells: The antigen-specific, murine T cell clone Ar-5 (Rao, A., Faas, S.J., and Cantor, H. (1984) *J. Exp. Med.* 159, 479-494) was maintained in Dulbecco's modified 25 Eagle's medium supplemented with 10% fetal calf serum, 10 mM Hepes, pH 7.4, 2 mM glutamine, 50 µM 2-mercaptoethanol, 50 units/ml penicillin, 50 µg/ml streptomycin, and 5-10 units/ml partially purified rat IL-2 (Collaborative Research). The murine fibroblast L 30 cell line was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 10 mM Hepes, pH 7.4, 50 units/ml penicillin, and 50 µg/ml streptomycin.

Preparation of cell extracts: To prepare hypotonic extracts, cells were harvested by centrifugation, washed

- 25 -

with phosphate buffered saline and resuspended to 10^8 cells/ml in buffer containing 7.5 mM Tris (pH 7.6), 2 mM PMSF, 1 mM MgCl₂, 0.5 mM DTT, 0.25 mM leupeptin, 0.1 mM EDTA and 1 mg/ml aprotinin. The cells were lysed by 5 quick-freezing in dry ice and rapid thawing in a room-temperature water bath, followed by centrifugation at 12,000 x g for 10 minutes. Where indicated, cells were treated before harvesting with 1 μ M CSA (Sandoz Corp.) or 100 nM FK506 (Fujisawa Pharmaceutical) for 10 minutes at 10 37°C.

In an alternative lysis protocol, extracts enriched for NF-AT_p were prepared by lysing unstimulated T cells (2.5×10^7 /ml) in a buffer containing 20 mM Tris pH 7.5, 10 mM iodoacetamide, 2 mM PMSF, 0.1 mM EDTA, 25 15 μ M leupeptin, 100 μ g/ml aprotinin and 0.05 % NP-40. The cell lysates were first centrifuged at 200 x g to remove nuclei, and then centrifuged further at 100,000 x g for 60'. The 100,000 x g supernatant was made up to 1.5 M in ammonium sulfate, and the precipitated proteins were 20 collected by centrifugation at 10,000 x g. The protein pellets were resuspended in buffer containing 100 mM NaCl, 20 mM Hepes, pH 7.4, 10 mM iodoacetamide, 2 mM EDTA, 2 mM PMSF, 25 μ M leupeptin, 100 μ g/ml aprotinin and 10% glycerol, and extensively dialyzed against the same 25 buffer without iodoacetamide and with 0.5 mM DTT.

For preparation of nuclear extracts from activated T cells, cells were incubated for two hours with cross-linked anti-CD3 ϵ monoclonal antibody (145-2C11, Kubo, R.T., Born, W., Kappler, J.W., Marrack, P., and Pigeon, 30 M. (1989) *J. Immunol.* **142**, 2736-2742) in the presence or absence of 1 μ M CSA. Activation conditions and preparation of nuclear extracts was exactly as previously described (McCaffrey, P.G., Jain, J., Jamieson, C., Sen, R., and Rao, A. (1992) *J. Biol. Chem.* **267**, 1864-1871). 35 Protein determinations were done by the method of

- 26 -

Bradford (Bradford, M. (1976) *Anal. Biochem.* **72**, 248-254), using bovine serum albumin as a standard.

Treatment of cell extracts with phosphatase in vitro:

Ammonium sulfate-precipitated protein (250 µg in 50 µl of buffer described above) were mixed with 1 µl calf intestinal phosphatase (Boehringer-Mannheim, 24 units/µl). For treatment with calcineurin, 250 µg of ammonium sulfate-precipitated protein was made up to 50 µl in 1.5 mM MnCl₂, 0.5 mM EDTA and 15 mM 2-mercaptoproethanol. Purified bovine brain calcineurin (King, M.M., and Heiny, L.P. (1987) *J. Biol. Chem.* **262**, 10658-10662) was added to 1 µM; calmodulin (Sigma) was added to 3 µM. All reactions were incubated at 30°C for 10-15 minutes. The reactions were stopped by the addition of SDS-PAGE sample buffer and boiling, and the proteins were fractionated by SDS-PAGE as described below.

Fractionation of cell proteins by SDS-PAGE, elution and renaturation: Hypotonic or nuclear extracts were boiled in SDS-PAGE sample buffer (65 mM Tris, pH 6.8, 2% SDS, 2% 2-mercaptoproethanol, 10% glycerol, 0.01 mg/ml bromphenol blue) and fractionated on 3 mm thick SDS-polyacrylamide gels by standard methods (Laemmli, U.K. (1970) *Nature* **227**, 680-685). Molecular weight standards (BioRad Laboratories) were also run on the same gel. After electrophoresis, the standards were cut off and separately stained. For recovery of proteins from the gels, slices (1 cm x 0.5 cm) from wet, unfixed gels were crushed and eluted overnight in 50 mM Tris, pH 7.9, 1 mM DTT, 0.2 mM EDTA, 0.1 mM PMSF, 0.1 mg/ml BSA, 2.5% glycerol and 0.1 % SDS (Baeuerle, P., and Baltimore, D. (1988) *Cell* **53**, 211-217). The eluted proteins (250 µl) were precipitated with 4 volumes of acetone at -20°C, washed with methanol at -20°C, air dried and resuspended in 2.5 µl of a saturated solution of urea. The urea was

- 27 -

diluted with 125 μ l of 20 mM Tris, pH 7.6, 10 mM KCl, 2 mM DTT and 0.1 mM PMSF, and the proteins were left overnight at 4°C to renature. To assess the recovery of proteins from individual gel slices, aliquots of 5 renatured proteins were electrophoresed on SDS-polyacrylamide minigels to separate the proteins derived from cell extracts from the carrier protein (BSA) added during elution. The gels were then stained using a sensitive silver stain procedure (Pierce Gelcode color 10 silver stain kit), and the equivalent recovery of proteins from different gel slices was confirmed.

Electrophoretic mobility shift assay: EMSAs were performed using 18 μ l of renatured proteins in a 30 μ l mix containing 4 mM Hepes, pH 7.4, 84 mM NaCl, 20 mM KCl, 15 0.08 mM EDTA, 9% glycerol, 0.7 mg/ml BSA, 17 μ g/ml poly(dI:dC) and 0.125 ng of 32 P-labelled oligonucleotide. For competition assays, a 200-fold excess of unlabeled oligonucleotide was added to the reaction. The reactions were incubated for 15 minutes at room temperature 20 followed by electrophoresis at 4°C on 4% Tris/borate/EDTA/acrylamide gels. The NF-AT oligonucleotide used had the sequence

GCCCAAAGAGGAAAATTGTTCATACAG (SEQ ID NO:1), corresponding to the distal NF-AT site from the murine 25 IL-2 promoter (nucleotides -295 to -267 relative to the transcription start site, (Serfling, E., Barthelmas, R., Pfeuffer, I., Schenk, B., Zarius, S., Swoboda, R., Mercurio, F., and Karin, M. (1989) EMBO J. 8, 465-473)). Oligonucleotides bearing mutations in the NF-AT site were 30 as follows: M1, GCCCAAAGAGGAAAATTGTTTATTCAG (SEQ ID NO:2); M2, GCCCAAAGAGGAAAATGGACTTCATACAG (SEQ ID NO:3); M3, GCCCAAAGACCTTATTGTTCATACAG (SEQ ID NO:4); where underlined nucleotides indicate changes made from the NF-AT sequence.

- 28 -

Analysis of renatured purified NF-AT_p: C1.7W2 cell extracts were prepared by NP-40 lysis and ammonium sulphate precipitation as described above. The precipitated protein (1.2 g from 10¹¹ cells) was dialyzed against 5 buffer A [150 mM NaCl, 20 mM HEPES (pH 7.4), 2 mM EDTA, 0.5 mM DTT, 10% glycerol], supplemented with protease inhibitors (100 mg/ml aprotinin, 2.5 mM leupeptin and 2 mM PMSF) and loaded onto a 30 ml heparin-agarose column (Sigma). The column was washed with 10 column volumes of 10 the same buffer containing 200 mM NaCl, and bound protein was eluted with a linear gradient of 0.2-1.0 M NaCl in a total volume of 250 ml. NF-AT_p activity was determined by EMSA. Active fractions were combined and dialyzed overnight against Buffer A. The dialyzed pool (90 ml, 95 15 mg protein) was loaded in 20 mg batches onto a 1 ml high capacity oligonucleotide affinity column in the presence of 200 µg/ml sheared herring sperm DNA. The column was washed with the same buffer, and NF-AT was eluted with a linear gradient of 0.15-1.0 M NaCl. The NF-AT activity 20 eluted in fractions between 0.4 M and 0.6 M NaCl. The peak fractions from several separate fractionations were combined, dialyzed against buffer containing 150 mM NaCl, and reloaded onto the same affinity column. After two cycles over the affinity column, approximately 10 µg of 25 highly purified NF-AT_p was obtained. This material bound specifically to the NF-AT site was a phosphoprotein substrate for calcineurin, and associated with c-Fos and c-Jun to form the NF-AT-Fos-Jun ternary complex on the NF-AT site oligonucleotide. Renaturation from gel slices 30 and EMASAs were performed as described above. The purified NF-AT_p protein was acetone precipitated, subjected to electrophoresis on a 6% SDS polyacrylamide gel, and transferred to nitrocellulose. The NF-AT_p band was localized by Ponceau Red staining, excised, and 35 digested with trypsin in situ. The resultant peptides

- 29 -

were separated by microbore HPLC. Isolated proteolytic fragments were then analyzed by laser desorption mass spectroscopy, and microsequenced using an automated amino acid analyzer (Edman degradation).

5 Cloning of the gene encoding murine NF-AT_p: Degenerate oligonucleotides based on the sequences of peptides 23.2 and 25 were used in a polymerase chain reaction to amplify an approximately 800-bp fragment from C1.7W2 cDNA. The fragment was used to screen an amplified cDNA library (representing 10⁶ primary plaques) in the vector λZAPII (Stratagene) generated by oligo(dT) and random priming of cytoplasmic poly(A)⁺ mRNA from Ar-5 T cells. After plaque purification of the recombinant λ bacteriophage clones and excision of pBluescript 10 phagemids carrying the cDNA inserts, the coding sequences of several cDNA clones were determined by sequencing both strands using the dideoxy chain termination method well known in the art.

A cDNA fragment common to all the alternatively spliced cDNAs was excised by digestion with Xho I and Sma I, subcloned into the vector pQE-31 (Qiagen), and expressed as a hexahistidine-tagged protein in bacteria. The expressed protein contained an additional 18 vector-encoded amino acids, MRGSHHHHHHTAPHASSV (SEQ ID NO:6) at 25 the NH₂-terminus, and 9 amino acids, VDLEPSLIS (SEQ ID NO:7) at the COOH-terminus, of the sequence indicated between the arrowheads in Fig. 10. The recombinant protein was purified by chromatography on a nickel-chelate column in 8 M urea, eluting with 250 mM imidazole. After dialysis against buffer A, the protein was assayed for DNA binding and Fos and Jun association.

In vitro transcription reactions: Nuclear extracts were made from Namalwa cells (ATCC Accession No. CRL 1432) as 35 described above. Fos and Jun proteins and truncated NF-

- 30 -

AT_p (NF-AT_pXS) were used at 500 μM and plasmid templates linearized by EcoRI were used at 80 μg/ml. Transcripts purified from the reactions were analyzed by polyacrylamide gel electrophoresis and quantitated using 5 a phosphorimager.

Characterization of murine NF-AT_p: To characterize the preexisting, DNA-binding component of NF-AT, we have used the murine IL-2 dependent T cell clone Ar-5. Activation of Ar-5 cells with monoclonal antibodies to the T cell 10 antigen receptor or its associated CD3 complex causes the rapid appearance in the nucleus of several inducible transcription factor including NF-AT, which is followed by expression of the IL-2 gene and cell proliferation (Jamieson, C., McCaffrey, P.G., Rao, A., and Sen, R. 15 (1991) *J. Immunol.* 147, 416-420). Induction of NF-AT subsequent IL-2 gene expression are completely blocked by CsA and FK506 in these cells. We have previously established that unactivated Ar-5 cells contain a protein or proteins, extracted under hypotonic lysis conditions, 20 that can bind in the EMSA to an oligonucleotide comprising the distal NF-AT sequence from the murine IL-2 promoter. Here we will refer to this NF-AT binding activity as NF-AT_p, to designate it as the subunit of NF-AT that is preexisting before T cell activation. 25 NF-AT_p can be detected as an approximately 120 kDa protein after renaturation from SDS-polyacrylamide gels: To determine an approximate molecular weight for NF-AT_p, we took advantage of the fact that some DNA-binding proteins retain their ability to bind DNA after elution 30 from SDS-PAGE gels and renaturation (Baeuerle and Baltimore (1988), *Cell*, 53:211-217 Briggs, M.R., Kadonaga, J.T., Bell, S.P., and Tjian, R. (1986) *Science* 234, 47-52). Hypotonic extracts from unstimulated Ar-5 T cells were fractionated by SDS-PAGE, followed by elution 35 and renaturation of proteins from individual gel slices

- 31 -

as described. As a negative control, we also tested extracts from a fibroblast cell line (L cells) that contained no detectable binding activity specific for the NF-AT oligonucleotide before fractionation. The 5 renatured proteins were assayed for DNA-binding by EMSA using an oligonucleotide spanning the distal NF-AT site of the murine IL-2 promoter. In T cell extracts, binding activity was detected in several slices containing proteins of apparent molecular weight 120 kDa and lower 10 (See Fig. 1A, slices 6-16). In L cell extracts, binding was detected using renatured proteins from the molecular weight range 66 kDa and lower (slices 11-18 of Fig. 1A).

Since NF-AT expression has been reported to be restricted largely to T and B cells (Verweij, C.L., 15 Guidos, C., and Crabtree, G.R. (1990) *Journal of Biological Chemistry* 265, 15788-15795) and we did not detect NF-AT binding in unfractionated L cell extracts, we considered the proteins of molecular weight lower than 66 KDa to be unlikely candidates for NF-AT_p.

20 Since nuclear extracts from activated T cells were expected to contain NF-AT_p as part of the multisubunit nuclear NF-AT complex, we asked whether such extracts contained NF-AT-binding proteins that were detectable after renaturation from SDS-polyacryamide gels. Nuclear 25 extracts containing NF-AT were prepared from Ar-5 T cells stimulated with an activating monoclonal antibody that reacts with the CD3ε subunit of the T cell antigen receptor/CD3 complex; these extracts were compared with nuclear extracts from unstimulated cells or cells 30 stimulated in the presence of 1 μM CsA that do not contain appreciable levels of NF-AT. After fractionation of nuclear extracts by SDS-PAGE, DNA-binding proteins were detected primarily in gel slices containing proteins of apparent molecular weight 102-122 and 86-102 kDa (Fig. 35 2A, lanes 5-12), and weakly in the gel slice containing

- 32 -

proteins of 122-144 kDa (Fig. 2A, lanes 1-4). An additional faint protein-DNA complex with a slower mobility was detected in the proteins from the 122-144 kDa range (lane 2); this complex is discussed below.

5 Nuclear extracts from stimulated T cells, which contain high levels of NF-AT, yielded the highest levels of DNA-binding proteins after fractionation on SDS-PAGE gels (compare lane 6 with lanes 5 and 8 of Fig. 2A). The yield of total protein from gel slices of each sample was
10 equivalent as assessed by SDS-PAGE and silver staining of the renatured proteins (data not shown; see Methods). In contrast to the results shown for hypotonic lysates, no additional DNA-binding proteins were detected in the lower molecular weight region of fractionated nuclear
15 extracts (data not shown), suggesting that only the proteins in the 86-144 kDa range of both hypotonic and nuclear extracts contained NF-AT_p.

The renatured DNA-binding proteins (90-140 kDa) from nuclear and hypotonic extracts were tested for binding
20 specificity for the NF-AT oligonucleotide by competition with oligonucleotides containing intact or mutated NF-AT sequences (Fig. 2B). By using these oligonucleotides in competition assays, we had previously defined a region in the distal NF-AT sequence critical for binding of both
25 NF-AT and NF-AT_p (Jain et al., Nature, 356:801-804). The M3 mutation disrupts this region, and thus this oligonucleotide fails to bind NF-AT (Jain, J., Miner, Z., and Rao, A., 1993, J. Immunol. 151:837-848) or to compete for NF-AT binding to the unmutated oligonucleotide. The
30 M1 mutation has no effect on the ability of the oligonucleotide to bind NF-AT, while M2 slightly impairs NF-AT binding. Similarly, the renatured proteins from either unactivated (hypotonic extract, Fig. 2B) or activated (nuclear extract, Fig. 2B) Ar-5 cells that
35 bound to the NF-AT oligonucleotide were completely

- 33 -

competed by the NF-AT oligonucleotide itself and by the M1 oligonucleotide, partially competed by the M2 oligonucleotide, and not competed at all by the M3 oligonucleotide. Thus, the 90-140 kDa proteins renatured 5 from hypotonic extracts of unactivated T cells or nuclear extracts of activated T cells displayed the same binding specificity as previously demonstrated for NF-AT_p and NF-AT. In contrast, the lower molecular weight DNA-binding proteins from either T cells or L cells were competed 10 poorly by either the intact or mutated NF-AT oligonucleotides, indicating that they did not interact specifically with the critical binding region of the NF-AT sequence defined by M3, and thus did not contain NF-AT_p.

15 Protease mapping experiments also provided evidence that the renatured proteins contained NF-AT_p. Treatment of hypotonic or nuclear extracts from Ar-5 cells with increasing amounts of V8 protease resulted in generation of two new major DNA-protein complexes in the gel shift 20 assay (Fig. 3, lanes 1-8). These new complexes presumably represent the binding of proteolytic fragments of NF-AT_p that retain their ability to interact with DNA. In agreement with this idea, V8 protease treatment of gel fractionated, renatured proteins from hypotonic extracts 25 (Fig. 3, lanes 9-12) or nuclear extracts (data not shown) caused generation of similar DNA-binding fragments. In addition, treatment of extracts or renatured proteins with chymotrypsin generated a set of DNA binding fragments distinct from those generated by V8 but similar 30 to each other. Protease treatment of nuclear extracts from unactivated cells that do not contain much NF-AT_p (see Fig. 2A) does not result in generation of any new DNA-protein complexes. In addition, neither V8 nor chymotrypsin alone had any detectable DNA-binding 35 activity in the gel shift assay. Thus, the new DNA-

- 34 -

protein complexes detected after protease treatment of crude extracts are most likely derived from NF-AT_p, and the similarity between the pattern seen with nuclear, hypotonic or renatured proteins is consistent with the 5 idea that the NF-AT-binding proteins in the renatured samples are related to the NF-AT_p polypeptides detected in the original nuclear and hypotonic extracts.

These results indicate that NF-AT_p, the DNA-binding subunit of NF-AT that is present in unstimulated 10 cells and appears in nuclear extracts upon T cell activation, migrates in SDS gels as a broad band of apparent molecular weight 90-140 kDa. By measuring the DNA-binding activity recovered in the 90-140 kDa region of the SDS-polyacrylamide gel, and comparing it to the 15 activity in the extracts originally loaded, we determined that the overall yield of NF-AT_p activity in the renaturation procedure was approximately 3%, a value consistent with the yield reported previously for elution and renaturation of the transcription factor Sp1. We 20 could also renature NF-AT_p after non-equilibrium pH gradient gel electrophoresis (NEPHGE, O'Farrell, P.Z., Goodman, H.M., and O'Farrell, P.H. (1977) *Cell* 12:1133). In this system, NF-AT_p also migrated as a single broad band, suggesting that it is composed of a family of 25 related proteins, or post-translationally modified variants of a single protein, or both.

NF-AT_p is a phosphoprotein: Since phosphorylation is a common source of protein size heterogeneity on SDS gels, and has important functional consequences for DNA-binding proteins, we examined the effect of exogenously 30 added phosphatase on NF-AT_p in cell extracts. In initial experiments, hypotonic extracts prepared by freeze-thawing and incubated for 10 min at 30°C in the presence or absence of calf intestinal phosphatase yielded NF-AT_p 35 migrating in the 90-120 kDa molecular weight range. When

- 35 -

extracts were prepared by an alternative procedure involving NP-40 lysis and enrichment of NF-AT_p by ammonium sulfate precipitation, NF-AT_p was recovered predominantly in the 113 to 127 kDa molecular weight fraction, and also to a small extent in the 127-143 kDa and 101-113 kDa fractions (Fig. 4A, left panel, -CIP). Treatment of the extracts with calf intestinal phosphatase (Fig. 4A, right panel, +CIP) resulted in the disappearance of the NF-AT_p complex (indicated by solid arrowhead) from the 127-143 kDa molecular weight fraction, and a concomitant increase in the intensity of the complex formed with proteins in the 101-113 kDa slice (Fig. 4A, right panel). An additional faint protein-DNA complex (Fig. 4A, left panel, open arrowhead) was detected using proteins in the 127-143 kDa molecular weight fraction. This complex binds the NF-AT oligonucleotide specifically, as judged by competition with intact or mutated oligonucleotides, but it does not shift in mobility on treatment with phosphatases (Fig. 4A and 4B) or CSA (see below). Although its relation to NF-AT_p is unknown, it serves as a useful control for evaluating changes in the apparent molecular weight of NF-AT_p. These results demonstrate that NF-AT_p is a phosphoprotein whose mobility in SDS-polyacrylamide gels can be altered by changes in its phosphorylation state.

Since NF-AT_p has been proposed to be a target for the calcium and calmodulin-dependent phosphatase calcineurin (protein phosphatase 2B), we tested the effect of this phosphatase on the mobility of NF-AT_p in SDS gels. Treatment of the ammonium sulfate precipitated proteins with purified bovine brain calcineurin (Fig. 4B) caused a decrease in the amount of the highest molecular weight form of NF-AT_p and an increase in the lower molecular weight form, although the change was not as dramatic as that seen with calf intestinal phosphatase.

- 36 -

These results suggest that NF-AT_p can be a direct substrate for the phosphatase calcineurin *in vitro*. NF-AT_p is a target for immunosuppressive drugs and calcineurin: The ability of the immunosuppressive agents 5 CsA and FK-506 to inhibit induction of NF-AT in activated T cells appears to result from their ability to inhibit the modification and perhaps the nuclear translocation of NF-AT_p. Recent studies have shown that CsA and FK506, in complex with their respective binding proteins 10 (immunophilins), can inhibit the activity of calcineurin *in vitro*, and also that calcineurin is inhibited in cell lysates from cells treated with CsA or FK506 prior to lysis. To test whether the phosphorylation state of NF-AT_p could be affected by treatment of cells with CsA, we 15 treated cells for 10 minutes with or without CsA prior to lysis by freeze-thawing, and fractionated the extracts on SDS-polyacrylamide gels. For these experiments, we chose to lyse by freeze-thawing because our previous experiments showed that NF-AT_p in such lysates would be 20 predominantly in the lower molecular weight form (see Fig. 1 for example), and previous reports demonstrated that lysates made under similar conditions from human Jurkat T cells contained active calcineurin. As expected, extracts from untreated cells contained NF-AT_p 25 activity predominantly in gel slices corresponding to a molecular weight range of 99 to 111 and 111 to 125 kDa (Fig. 5A, lanes 4 and 5). In contrast, extracts from CsA-treated cells contained more activity in the 125-140 kDa range, and very little in the 99-111 kDa range (Fig. 30 5B, lanes 3 and 5). Similar results were seen after treatment of cells with FK506. This change in apparent molecular weight was specific for NF-AT_p, since proteins eluting in the lower molecular weight areas of the gel maintained their relative mobilities (see lanes 6-13). 35 In addition, the change was specific for the predominant

- 37 -

NF-AT_p complex (solid arrowhead), and did not affect the faint upper complex (lane 3, open arrowhead), and thus was consistent with the sensitivity of the complexes to CIP and calcineurin treatment (Fig. 4A and 4B). The 5 apparent change in molecular weight of NF-AT_p upon CsA treatment was not due to the presence of inhibitors in the renatured proteins that masked binding activity, since mixed lysates contained activity in each slice in the range 99-145 kDa (Fig. 5C). The proteins detected in 10 each slice bound specifically as shown by competition, and were shown to be related by protease mapping.

To test directly whether activation of calcineurin during cell lysis was causing the appearance of the lower molecular weight form of NF-AT_p, we lysed cells in the 15 presence of a specific peptide inhibitor of calcineurin (Hashimoto, Y., Perrino, B.A., and Soderling, T.R. (1990) *J. Biol. Chem.* 265, 1924-1927) or in the presence of a mutated peptide that lacked calcineurin inhibitory activity (Perrino and Soderling, unpublished results). 20 Inhibition of calcineurin activity by inclusion of the specific peptide inhibitor in the cell lysis buffer resulted in the appearance of the higher molecular weight form of NF-AT_p, while lysis in the presence of the non-inhibitory (control) peptide resulted in detection of the 25 lower molecular weight form (Fig. 6). Since our lysis buffer contained no EGTA, it was conceivable that the activation of calcineurin was resulting from calcium release during cell lysis. In agreement with this idea, inclusion of 2 mM EGTA in the cell lysis buffer resulted 30 in recovery of the higher molecular weight form of NF-AT_p (data not shown). Together, these results are consistent with the hypothesis that NF-AT_p is a substrate for calcineurin in cell lysates, and that CsA and FK506 act to inhibit dephosphorylation of NF-AT_p in cell lysates by 35 inhibiting calcineurin.

- 38 -

Analysis of purified NF-AT_p: NF-AT_p was purified from the Cl.7W2 cell line, a derivative of the murine T cell clone Ar-5, by ammonium sulfate fractionation followed by successive chromatography on a heparin-agarose column and 5 an NF-AT oligonucleotide affinity column. A silver-stained SDS gel of the purified protein showed a major broad band migrating with an apparent molecular weight of approximately 120 kDa (Fig. 8, top panel). This band contains a DNA-binding phosphoprotein that is dephosphorylated by calcineurin to yield four sharp bands 10 migrating with apparent molecular weights of approximately 110-115 kDa. NF-AT_p DNA-binding activity was demonstrable in protein eluted from the SDS gel and renatured, and more than 90% of the activity recovered 15 from the gel comigrated with the approximately 120 kDa band (Fig. 8, lane 7). The faster-migrating complexes formed with proteins of slightly lower molecular weight (lanes 8-11) most likely derive from partial proteolysis. The purified protein binds to the NF-AT site with the 20 appropriate specificity, and forms a DNA-protein complex with recombinant Fos and Jun.

Antisera to tryptic peptides binds to NF-AT_p in T cell extracts: Antisera to tryptic peptides derived from the 120 kDa protein to confirm that the 120 kDa protein was 25 the preexisting subunit of the T cell transcription factor NF-AT. When one such antiserum (raised against a 21-residue synthetic fragment containing residues 206-227 of peptide 72 shown in Fig. 10) was included in the binding reaction, it "supershifted" the NF-AT_p-DNA 30 complex formed by the cytosolic fraction from unstimulated T cells (Fig. 9, lane 3), as well as both NF-AT complexes formed by nuclear extracts from stimulated T cells (lane 8). The effect of the serum was prevented by preincubation with its cognate peptide (lanes 4 35 and 9), but not by preincubation with a different peptide

- 39 -

(lanes 5 and 10). Preimmune serum had no effect on binding (lanes 2 and 7). Similar effects were seen with antisera to peptides 23.1 and 25. These data demonstrate that the purified protein is NF-AT_p.

5 **Identification of a murine NF-AT_p cDNA clone.** In order to isolate a cDNA clone encoding NF-AT_p, degenerate oligonucleotides based on the sequences of two tryptic peptides of purified NF-AT_p were used in a polymerase chain reaction (PCR) to amplify an approximately 800-bp
10 fragment from Cl.7W2 cDNA, and the fragment was used to screen a cDNA library from murine T cells. The clone containing the longest cDNA insert, mNF-AT_pQ1B1/A, contains an insert of about 4.5 kb in length, with an open reading frame extending 2,672 bp from the 5' end of
15 the insert and with about 1.8 kb of 3' untranslated region that does not extend to the poly(A) tail. The open reading frame encodes a polypeptide of 890 amino acids (SEQ ID NO:5) (Fig. 10) that contains eight of nine tryptic peptides identified by sequencing of purified NF-
20 AT_p. The cDNA insert lacks a small amount of coding sequence at the 5' end, because the predicted molecular weight of the encoded protein (97 kD) is somewhat smaller than the apparent molecular weight of dephosphorylated NF-AT_p (110-115 kD), and because one tryptic peptide from
25 purified NF-AT_p is unaccounted for in the encoded protein. A search of the GenBank DNA and protein databases with the Blast algorithm (Altschul et al., (1990) *J. Mol. Biol.* 215:403-410) indicated that the cDNA encodes a novel protein. A 464-amino-acid fragment
30 containing the DNA-binding domain displayed a limited similarity to the rel homology domain of human and murine RelA (p65) (18.9% and 17.8% amino acid identity, respectively, over 428 amino acids). A preliminary analysis of additional cDNA clones indicates that T cells
35 express at least three forms of NF-AT_p related to each

- 40 -

other by alternative splicing and differing at their COOH-termini.

- Cell-specific expression of NF-AT_p RNA:** Consistent with the previous demonstration that NF-AT_p protein is present 5 in T cells but not in L cells, the T cell lines Cl.7W2 and Ar-5, but not L cells, were found to express NF-AT_p mRNA (Fig. 11). The PCR fragment of approximately 800 bp hybridized to a transcript of about 8-9 kb expressed in the Cl.7W2 T cell line used for purification of NF-AT_p 10 (lane 1) and in the untransformed T cell clone Ar-5 used to generate the cDNA library (lane 2), but did not hybridize to any transcript expressed in L cells (lane 3). Two other cDNA probes representing different parts of the coding region of NF-AT_p gave similar results.
- 15 Systematic analysis of the tissue distribution of NF-AT_p can be accomplished by Western analysis, quantitative PCR, or Northern blot analysis.
- Binding specificity of recombinant murine NF-AT_p:** To test directly whether the cDNA encoded a protein with the 20 characteristics of NF-AT_p, the ability of a recombinant fragment of the protein to bind to the NF-AT site of the murine IL-2 promoter and to associate with Fos and Jun was evaluated. Using the QIAexpress Kit (QIAGEN, Inc.), 464-amino-acid fragment of the protein (sequence between 25 arrowheads in Fig. 10) (SEQ ID NO:21) was expressed as a hexahistidine-tagged protein in bacteria using the pQE31 vector. This recombinant protein bound to the NF-AT binding site oligonucleotide in a gel shift assay (Fig. 12, lane 1). Its binding specificity was identical to 30 that of authentic T cell NF-AT_p, as judged by competition with excess unlabeled NF-AT binding site oligonucleotide (lane 2) and the mutant NF-AT oligonucleotides M1-M3 (lanes 3-5). The M1 oligonucleotide (lane 3) is mutated in four bases remote from the NF-AT binding site, and 35 competes as strongly for binding as the authentic NF-AT

- 41 -

oligonucleotide; the M2 oligonucleotide (lane 4) is mutated in four bases located between the M1 and M3 regions, and competes with intermediate efficiency; and the M3 oligonucleotide (lane 5) is mutated in the GGAA tetranucleotide sequence essential for binding of NF-AT_p, and does not compete for binding. Methylation interference analysis also showed that binding of the recombinant protein to the NF-AT site required the GGAA core binding region, as previously demonstrated for NF-AT. Like NF-AT_p purified from T cells, the recombinant protein associated with homodimers of c-Jun or with heterodimers of c-Fos and c-Jun, but not with c-Fos alone, to form a DNA-protein complex that migrated with slower mobility than the NF-AT_p-DNA complex in an EMSA (lanes 7-9). c-Fos and c-Jun do not bind to the NF-AT oligonucleotide in the absence of NF-AT_p (lane 10). The complex containing c-Fos and c-Jun resembled the nuclear complex of NF-AT_p, Fos, and Jun in that its formation was competed by excess unlabeled AP-1 oligonucleotide. These data indicate that a fragment of NF-AT_p of approximately 50 kDa is sufficient to account for the DNA binding properties of NF-AT_p and for its ability to associate with Fos and Jun proteins.

Antisera to recombinant NF-AT_p recognize NF-AT_p in T cell extracts: Definitive evidence that the cDNA clone encodes NF-AT_p was provided by the ability of antisera to the recombinant protein to react specifically with NF-AT_p from cytosolic or nuclear extracts of T cells. When serum from a rabbit immunized with the recombinant protein was included in the EMSA, a small proportion of the NF-AT_p-DNA complexes were "supershifted" (Fig. 13, lane 3) and most of the DNA-protein complexes appeared to be in large aggregates (lanes 3 and 7). The predominance of large aggregates probably reflects recognition by the serum of multiple antigenic determinants on NF-AT_p.

- 42 -

Preimmune serum from the same rabbit did not alter the mobility of NF-AT_p-DNA and NF-AT-DNA complexes (lanes 2 and 6).

Transcriptional activation by NF-AT_p, c-Fos, and c-Jun on 5 different templates. To examine the role of the cloned NF-AT_p protein in transcription, the effect of the recombinant NF-AT_p fragment on transcription in vitro from a template containing three NF-AT sites upstream of the murine IL-2 promoter was tested (Fig. 14). The same 10 plasmid has been used to demonstrate transcriptional activation *in vivo* in response to stimulation with antigen (Jain et al., (1993), *J. Immunol.* 151:837). A combination of the recombinant NF-AT_p fragment with c-Fos and c-Jun, or with c-Jun only, activated transcription 15 from this construct (Fig. 14, lanes 2 and 3). In combination with NF-AT_p, a Jun deletion derivative (J91-334) lacking the amino-terminal repressor domain was a more potent activator than full-length Jun (lanes 6, 7, and 14), as previously observed for transcriptional 20 activation by Jun at AP-1 sites (Kerppola et al., (1993), *Mol. Cell Biol.* 13:3782). In contrast, neither the truncated NF-AT_p alone nor AP-1 proteins alone had a significant effect (lanes 5, 10, and 11). Truncated Fos and Jun 25 proteins (F139-200 and J241-334) containing the dimerization and DNA-binding domains, but lacking transcriptional activation domains, are able to form a complex with NF-AT_p. However, the truncated proteins did not activate transcription in conjunction with truncated NF-AT_p (lanes 8 and 9), indicating that the truncated NF-AT_p is not 30 transcriptionally active in the absence of Fos and Jun. No significant transcriptional activation was observed when a template containing a mutated NF-AT site incapable of binding NF-AT_p was used (lanes 15-17). Moreover, the truncated NF-AT_p had no effect on transcription activated 35 by Fos and Jun on a template containing an AP-1 site

- 43 -

(lanes 18-24), consistent with the observation that NF-AT_p does not form a complex with Fos and Jun on the AP-1 site.

These data show that truncated NF-AT_p forms a transcriptionally active complex with Fos and Jun at the IL-2 promoter NF-AT site, and are consistent with the interpretation that NF-AT_p primarily determines the DNA-binding specificity of the NF-AT complex *in vivo*, whereas at least a portion of the transcriptional activity is provided by Fos and Jun. Since the current experiments were performed using a truncated NF-AT_p, they do not exclude the possibility that full-length NF-AT_p possesses a transcriptional activation domain that can function in the absence of Fos and Jun. However, there is evidence suggesting that Fos and Jun family proteins are required along with NF-AT_p to activate transcription at the IL-2 promoter NF-AT site *in vivo*, since mutations in the NF-AT site that prevent the association of Fos and Jun with NF-AT_p abolish the function of this site in activated T cells.

The cDNA clone reported herein fulfills four essential criteria defining NF-AT_p: the mRNA is expressed in T cells but not in fibroblasts, a recombinant fragment of the protein binds specifically to the NF-AT site, the recombinant protein fragment forms a transcriptionally active complex with Fos and Jun on the NF-AT DNA sequence, and antibodies directed against the recombinant protein recognize NF-AT_p in T cell extracts. The recombinant protein defines a functional 464-amino-acid fragment of NF-AT_p that contains the domains required for DNA binding and for formation of a transcriptionally active complex with Fos and Jun. The cloning of this novel DNA-binding protein makes possible detailed studies of its structure, its interactions with other transcription factors and with specific sites in DNA, its

- 44 -

role in the induction of IL-2 and other cytokine genes, and its regulation by calcineurin during T cell activation.

Murine NF-AT_p isoforms: Fig. 19 shows the partial cDNA sequence of murine NF-AT_p from the cDNA insert of the deposited plasmid, mNF-AT_p-Q1B1/A (designated by "m") Additional cDNA clones of murine NF-AT_p have been identified. Sequence analysis of the cDNA inserts revealed the existence of alternatively spliced isoforms of NF-AT_p. The alternatively spliced forms that have been isolated are identical in sequence to mNF-AT_p-Q1B1/A in the region up to and including nucleotide 2208 of mNF-AT_p-Q1B1/A (see Fig. 20).

Cloning of the human homolog of murine NF-AT_p: Four fragments of the coding sequence of murine NF-AT_p cDNA have been characterized for use as probes to isolate the human cDNA. Two are restriction fragments that can be prepared from plasmid mNF-AT_p-Q1B1/A: a fragment that extends from the EcoRI site in the multiple cloning site of the vector to the EcoRI site at nucleotide 570 of the insert ("EcoRI fragment"), and a fragment that extends from the PstI site at nucleotide 646 of the cDNA to the PstI site at nucleotide 1169 ("PstI fragment"). The third fragment which is approximately 800 bp ("~800 bp PCR product") is a cDNA fragment amplified from mouse T cell cDNA by the polymerase chain reaction (PCR), and which corresponds to the region between nucleotides 1314 and 2089 in plasmid mNF-AT_p-Q1B1/A. The fourth fragment corresponds to the region between nucleotides 1849 and 2089 in the plasmid, and is obtained from the ~800 bp PCR product by digestion with SphI ("SphI-3' fragment").

The cDNA probes described above are sufficient to identify human cDNAs representing the entire coding sequence of NF-AT_p, including cDNAs that have a region in common with these probes and encode isoforms of NF-AT_p.

- 45 -

that are related by alternative splicing. The fragments specified for use as probes span the region common to all the splicing variants of NF-AT_p cDNA that have been identified in the mouse T cell, with the exception of the 5 extreme 5' end of the coding sequence, a region of the human cDNA that has been isolated already in human clone hNF-AT_p-21B2. Radiolabelled probes made from the EcoRI fragment, the PstI fragment, and the SphI-3' fragment form stable hybrids with a single human gene (under the 10 same conditions used for screening cDNA libraries) as demonstrated directly by Southern hybridization to restriction enzyme-digested human genomic DNA. Specific binding of the EcoRI fragment and the SphI-3' fragment in a Southern hybridization is shown in Fig. 15 and 16, 15 respectively.

The experiment shown Fig. 15 and 16 indicates that these murine cDNA probes satisfy the two essential conditions for their use in screening human cDNA libraries: the probes form DNA hybrids with the human 20 sequences that are sufficiently stable to survive washing under moderate stringency or high stringency conditions; and they do not label multiple DNA fragments in human genomic DNA, indicating that a high background of false positive signals (due to nonspecific hybridization or 25 hybridization to repeated sequences) is unlikely to occur in screening the cDNA libraries.

The EcoRI fragment probe from mouse cDNA has been used to isolate a partial length cDNA encoding human NF-AT_p (hNF-AT_p-21B2) from a human Jurkat T cell cDNA 30 library, further demonstrating that the murine cDNA probes can efficiently identify human cDNA clones containing NF-AT_p coding sequences. Since the EcoRI fragment identifies a single gene in Southern analysis of human genomic DNA, it was likely *a priori* that the hNF-35 AT_p-21B2 cDNA represented human NF-AT_p. Direct evidence

- 46 -

that this clone encodes human NF-AT_p is that the predicted sequence of the encoded protein is ~90% identical at the amino acid level to that of mouse NF-AT_p (encoded by mNF-AT_p-Q1B1/A) in the region of overlap, 5 which extends for 243 amino acids. Further, the coding sequence of hNF-AT_p-21B2 cDNA in the region 5' to its overlap with the known mouse NF-AT_p sequence encodes a peptide very closely related (identical at 30/32 positions) to a tryptic peptide of purified NF-AT_p, 10 protein from mouse T cells. Although this peptide was known from microsequencing of the purified mouse protein, it is not encoded in the partial length mouse cDNA mNF-AT_p-Q1B1/A, and was therefore expected to be encoded near the 5' end of the NF-AT_p coding sequence.

15 In a parallel strategy to identify human NF-AT_p cDNA clones, a fragment of the human cDNA that represents the 3' end of the partial-length cDNA already obtained can be used to screen the human T cell cDNA libraries. A suitable KpnI-EcoRI restriction fragment can be prepared 20 from plasmid hNF-AT_p-21B2. This cDNA fragment extends from a KpnI site in the cDNA insert (corresponding to the KpnI site at nucleotide 369 of the mouse cDNA) to the EcoRI site in the multiple cloning site of the pBluescript vector. This KpnI-EcoRI fragment of the 25 human cDNA overlaps the EcoRI fragment of mouse cDNA, and offers the slight advantage that replica filters of the cDNA library can be washed at even higher stringency than is possible with the mouse cDNA probes.

Using reagents derived from the mouse cDNA clone 30 mNF-AT_p-Q1B1/A and the human cDNA clone hNF-AT_p-21B2, the isolation of a full-length human NF-AT_p cDNA is well within the skill of those skilled in the art of molecular biology. For example, radiolabelled cDNA probes made from the cDNA inserts of murine clone, mNF-AT_p-Q1B1/A, 35 and human clone, hNF-AT_p-21B2, can be used to identify

- 47 -

and isolate cDNAs, present in cDNA libraries from human T cells that contain regions with sequence homology to these cDNAs. The following paragraphs describe murine cDNA probes that have been demonstrated to form

- 5 sufficiently stable hybrids with human NF-AT_p DNA for efficient screening of cDNA libraries; a human cDNA probe for screening cDNA libraries; the availability of cDNA libraries from human T cells; the specific methods that will be used to isolate cDNAs encoding human NF-AT_p; and
10 the methods for characterization of these cDNAs.

Preparation and labelling of cDNA probes for isolation of full-length human NF-AT_p clone: Restriction fragments can be prepared from the plasmids mNF-AT_p-Q1B1/A and hNF-AT_p-21B2 by digestion with the restriction enzyme(s)

- 15 (EcoRI; PstI; or KpnI and EcoRI) specified above, and purified by agarose gel electrophoresis in low-melting-temperature agarose, followed by excision of the appropriate ethidium-bromide-stained band, and recovery of DNA from the agarose using methods well known in the
20 art (Sambrook et al, *supra*). The purified DNA probe can then be radiolabelled by a random priming method using a kit supplied by Boehringer Mannheim, according to a protocol from Boehringer Mannheim.

- The ~800 bp PCR product and its SphI-3' fragment
25 can be prepared using routine methodology in the following sequence of steps: preparation of RNA; synthesis of cDNA; PCR amplification; and digestion with restriction enzyme. RNA can be isolated from mouse T cells, and enriched for mRNA by selection on oligo(dT)-
30 cellulose (Sambrook et al., *supra*).

cDNA can be synthesized using random hexanucleotide primers by known methods, briefly described as follows. In a silanized tube, 1 µg poly(A)⁺ RNA (obtained by selection on oligo(dT)-cellulose) and
35 100 pmol random hexanucleotides (Pharmacia) are mixed in

- 48 -

a total volume of 10 μ l RNase-free water. The tube is heated at 95°C for 3 min., chilled on ice, and centrifuged to bring all the liquid to the bottom of the tube. Then 10 μ l of a reaction mixture [2x MMLV buffer

5 (GIBCO-BRL); 20 mM DTT; 2 mM of each of the 2'-deoxynucleoside 5'-triphosphates dATP, dCTP, dGTP, dTTP (Ultrapure dNTP Set, Pharmacia); and 20 U/ μ l MMLV reverse transcriptase (GIBCO-BRL)] is added, the reaction is incubated at 22°C for 10 min, and further incubated at

10 42°C for 60 min. PCR amplification primed by the oligonucleotides shown below is performed in a 100 μ l reaction volume [containing 20 mM tris HCl, pH 8.3 at 20°C; 25 mM KCl; 2 mM MgCl₂; 100 μ g/ml BSA; 40 pmol of each oligonucleotide primer; 50 μ M of each of the 2'-

15 deoxynucleoside 5'-triphosphates dATP, dCTP, dGTP, dTTP; 2 U Taq polymerase (Perkin-Elmer Cetus); and 1 μ l cDNA from the above cDNA synthesis reaction]. After preparation of the reaction mixture it is overlaid with mineral oil, and subjected to the following series of

20 steps in a thermal cycler: 3 min at 72°C; 5 min at 95°C; 30 sec at 55°C; then 35 sequential cycles [2 min at 72°C; 30 sec at 95°C; 30 sec at 55°C]; then 5 min at 72°C.

This typical PCR protocol is based on that recommended by Innis MA and Gelfand DH, (1990), Optimization of PCRs, In

25 PCR Protocols, Innis MA, Gelfand DH, Sninsky JJ, and White, TJ, editors, Academic Press (San Diego).

Digestion with SphI, purification of the SphI-3' fragment by agarose gel electrophoresis, and radiolabelling of the DNA fragment can be performed using procedures described

30 above.

The following sequences of degenerate oligonucleotide primers can be used in preparation of the ~800 bp PCR product:

5'-CGTTCGGATCCAGTGTT (TC) ATGGAGAA (AG) ACTACA-3' (SEQ ID
35 NO:9)

- 49 -

5' -CGACAGGATCCTG (TC) TGIATIACIGTIGG (GA) TA (CTGA) GC-3' (SEQ
ID NO:10). The upper sequence is that of the sense
strand primer, and the lower sequence that of the
antisense strand primer. "A", "C", "G", and "T" are the
5 standard single-letter abbreviations for the nucleotide
bases; "I" represents inosine; letters enclosed in
parentheses represent sequence degeneracy, and indicate
which bases are present at that position in the
oligonucleotide. Bold type represents the portion of the
10 primer that is expected to anneal to NF-AT_p coding
sequence; the remainder of each oligonucleotide
incorporates a restriction site and a "GC clamp".
Although primers exactly matched to the known sequence of
the murine cDNA would be expected to yield the same
15 product, the PCR conditions described have been developed
for these degenerate primers, and routinely give the
desired product.

Since the present application discloses both
murine and human NF-AT_p sequence and makes available
20 plasmids containing such sequence, obtaining the complete
sequence of NF-AT_p is a simple matter of applying routine
hybridization techniques to one or more appropriate cDNA
libraries (e.g., T cell cDNA libraries). To ensure that a
full-length cDNA or overlapping cDNAs representing the
25 entire coding sequence will be obtained, more than one
cDNA library of 1-5 million independent clones can be
screened. Several cDNA libraries from human T cells are
available from commercial sources, e.g., Clontech.

In the event that it becomes necessary to prepare
30 additional cDNA libraries from human T cells for the
purpose of obtaining a full-length cDNA clone, cDNA
libraries with greater than 1 million independent clones
can be prepared either by commercial services for a fee
(for example, Stratagene, Inc. offers this service), or
35 by a researcher in the laboratory using standard

- 50 -

techniques and commercially available reagents (supplied, for example, by Stratagene, Inc. or by Promega) that have been optimized for the steps of cDNA synthesis, ligation to λ bacteriophage arms, packaging into λ bacteriophage 5 particles, and infection of host cells. To ensure that the entire coding region of the NF-AT_p mRNA is represented, the cDNA can be synthesized both with oligo(dT) priming and with random priming.

Methods for screening cDNA libraries: The screening of 10 replica filters of cDNA libraries with radiolabelled cDNA probes is routine in the art of molecular biology. Plating of the cDNA library; preparation of replica filters; hybridization with radiolabelled probe and washing; identification of positive plaques by alignment 15 of an autoradiograph of the filter with the original plate; and plaque purification of individual clones that contain cDNA hybridizing with the probe have been described in detail by Sambrook et al. *supra*.

Methods for isolation and sequence analysis of cDNAs. 20 The isolation and sequencing of a phage or plasmid clone previously determined to contain the cDNA of interest, i.e., human NF-AT_p, can be performed using routine methodology. For example, to isolate NF-AT_p cDNA clones from libraries in the λ ZAPII vector, a pBluescript 25 plasmid vector carrying the cDNA insert can be excised according to the protocol that is supplied by the manufacturer, e.g., Stratagene, Inc., with the vector or with commercially-available cDNA libraries made in the vector, λ ZAPII. Individual colonies of bacteria 30 containing the resulting plasmid can be grown on ampicillin-containing medium, and plasmid DNA can be prepared by standard techniques (Sambrook et al, *supra*). If libraries made in other λ phage vectors are used, bacteriophage λ vector DNA containing the cDNA insert can 35 be isolated from individual λ clones (after plaque

- 51 -

purification) using known methods (Sambrook et al, supra), and digested using the appropriate restriction enzymes to obtain the cDNA insert or cDNA insert fragments. These cDNAs can then be subcloned into a 5 plasmid vector (e.g., pBluescriptII), and the plasmid DNA purified by standard techniques. The sequence of each cDNA insert can be determined (on both strands) using the dideoxy chain termination method well known in the art (Sanger et al, supra; Sambrook et al, supra).

10 **Identification and characterization of a human NF-AT_p cDNA clone.**

The plasmid hNF-AT_p-21B2 which has been deposited with the ATCC contains a cDNA insert representing a portion of the coding sequence of human NF-AT_p. Fig. 17 15 (SEQ ID NO:11) depicts a partial sequence of the cDNA insert of clone hNF-AT_p-21B2. "—" denotes approximately 1.9 kb of cDNA insert, expected to be principally 5' untranslated region, that has not yet been sequenced. "_" indicates a gap introduced in the human 20 sequence to maintain alignment with the known murine sequence in the region of overlap. Fig. 18 (SEQ ID NO:12) shows the amino acid sequence deduced from the cDNA insert of hNF-AT_p-21B2.

Fig. 19 shows an alignment of the murine 25 (SEQ ID NO:8) and human (SEQ ID NO:22) NF-AT_p cDNA sequences in the region of overlap. The region of overlap corresponds to 732 bp at the 5' end of the murine cDNA insert. In this figure, "_" indicates identity and " ." indicates a gap introduced in the human sequence to 30 maintain alignment with the murine sequence. This provisional human sequence appears to contain an in-frame stop codon, TGA, between bp 650-660 as shown in Fig. 19. Considering the homology between the human and murine sequences and the tryptic peptide data, this in-frame

- 52 -

stop codon probably represents a sequencing error.
Careful sequence analysis of the deposited human cDNA
clone, hNF-AT_p-21B2, is likely to resolve the
discrepancy.

5 Deposit

Under the terms of the Budapest Treaty on the
International Recognition of the Deposit of
Microorganisms for the Purpose of Patent Procedure,
deposit of the following materials has been made with the
10 American Type Culture Collection (ATCC) of Rockville, MD,
USA.

Applicants' assignees, President and Fellows of
Harvard University and Dana-Farber Cancer Institute,
Inc., represent that the ATCC is a depository affording
15 permanence of the deposit and ready accessibility thereto
by the public if a patent is granted. All restrictions
on the availability to the public of the material so
deposited will be irrevocably removed upon the granting
of a patent. The material will be available during the
20 pendency of the patent application to one determined by
the Commissioner to be entitled thereto under 37 CFR 1.14
and 35 U.S.C. §122. The deposited material will be
maintained with all the care necessary to keep it viable
and uncontaminated for a period of at least five years
25 after the most recent request for the furnishing of a
sample of the deposited plasmid, and in any case, for a
period of at least thirty (30) years after the date of
deposit or for the enforceable life of the patent,
whichever period is longer. Applicants' assignee
30 acknowledges its duty to replace the deposit should the
depository be unable to furnish a sample when requested
due to the condition of the deposit.

Plasmid hNF-AT_p-21B2 containing the human NF-AT_p
sequence and the plasmid mNF-AT_p-Q1B1/A containing the
35 murine NF-AT_p sequence have been deposited on October 28,

- 53 -

1993 with the American Type Culture Collection (Rockville, MD) and have received ATCC designations 75598 and 75597, respectively.

Alternative cloning strategies: Since the amino acid sequence of purified NF-AT_p has been determined, obtaining a full length NF-AT_p clone and any alternatively spliced isoforms can be accomplished using any one of a number of techniques known to those skilled in the art. Such cloning techniques are described in detail in Molecular Cloning: A Laboratory Manual, Sambrook et al. 1989, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Three well known alternative cloning strategies are described below.

Based on the amino acid sequence of purified NF-AT_p, two PCR primers of approximately 15 nucleotides can be synthesized corresponding to either end of a length of a NF-AT_p peptide of approximately 40 amino acid residues. cDNA can be prepared from 100 mg of total RNA obtained from a cell previously determined to express NF-AT_p, e.g., AR-5 cells. The primers are added to the cDNA with standard PCR components and the mixture is incubated under standard PCR conditions. Amplified fragments can be separated by electrophoresis and subcloned into a sequencing vector, for example, Bluescript (Stratagene, La Jolla, CA), by blunt end ligation. Alternatively, restriction enzyme sites can be incorporated into the PCR primers and the PCR product digested with the appropriate restriction enzyme and ligated to a vector which has been digested with a restriction enzyme to produce compatible sticky ends. The PCR-derived NF-AT_p insert DNA can be sequenced using known methods e.g., the dideoxy-chain-termination method, utilizing e.g., SEQUENASE® DNA polymerase (United State Biochemical Corp.) (Sanger F. et al., (1977), Proc. Natl. Acad. Sci. USA 74:5463-5467). DNA fragments so isolated can be used as hybridization

- 54 -

probes to screen for overlapping cDNA inserts in a cDNA library prepared from cells known to express NF-AT_p, e.g., Ar-5 cells. Positive clones can be isolated and the DNA sequenced and compared with that of the available 5 amino acid sequence. Oligonucleotide primers corresponding to bordering vector regions as well as NF-AT_p primers prepared from previously isolated cDNA clones can be employed to progressively determine the sequence of the entire gene.

10 Fragments of DNA containing sequences that correspond to the amino acid sequence of NF-AT_p can be recloned into an expression vector, using a variety of methods known in the art. For example, a recombinant NF-AT_p polypeptide can be expressed as a fusion protein with 15 maltose binding protein produced in *E. coli*. Using the maltose binding protein fusion and purification system (New England Biolabs), the cloned NF-AT_p sequence can be inserted downstream and in frame of the gene encoding maltose binding protein (*malE*), and the *malE-NF-AT_p* 20 fusion protein can then be overexpressed. In the absence of convenient restriction sites in the NF-AT_p, PCR can be used to introduce restriction sites compatible with the vector at the 5' and 3' end of the cDNA fragment to facilitate insertion of the cDNA fragment into the 25 vector.

Following expression of the fusion protein, it can be purified by affinity chromatography. For example, the fusion protein can be purified by virtue of the ability of the maltose binding protein portion of the fusion 30 protein to bind to amylose immobilized on a column. Alternatively, an antibody specific for the NF-AT_p portion of the fusion protein can be immobilized on a column and the fusion protein purified by virtue of the NF-AT_p portion of the protein binding to immobilized NF-35 AT_p specific antibody or NF-AT oligonucleotide.

- 55 -

To facilitate protein purification, the pMalE plasmid contains a factor Xa cleavage site upstream of the site into which the cDNA is inserted into the vector. Thus, the fusion protein purified as described above can 5 then be cleaved with factor Xa to separate the maltose binding protein from recombinant NF-AT_p. The cleavage products can be subjected to further chromatography to purify the NF-AT_p from the maltose binding protein.

The recombinant NF-AT_p can be tested for 10 functional activity, such as binding specifically to the NF-AT_p site, the ability to associate with c-Fos and C-Jun to form the NF-AT_p-Fos-Jun ternary complex on the NF-AT_p site oligonucleotide, and the ability to act as a substrate for calcineurin.

15 Using another cloning strategy, synthetic degenerate oligonucleotides corresponding to stretches of 10-20 amino acid residues of NF-AT_p can be made using an oligonucleotide synthesizer. These oligonucleotides can be used as hybridization probes to screen a cDNA library 20 as described above. Positive clones can be sequenced, the sequence compared to the known amino acid sequence, and functional activity encoded by these DNAs tested as described above.

The gene encoding NF-AT_p can also be identified 25 using expression cloning techniques. In this case, the binding of NF-AT_p-specific antisera or monoclonal antibodies can be used to screen an expression library. Antibodies can be raised in an animal, for example, a rabbit, using as immunogens purified fragments of NF-AT_p 30 obtained as described above. These antibodies are labeled with a suitable label and are then used as probes to screen an expression library, e.g., a bacteriophage λ expression library generated by cloning cDNA from cells previously determined to express NF-AT_p. Positive clones 35 are identified based on NF-AT_p-specific antibody binding.

- 56 -

Clones identified in this manner can be isolated,
sequenced and tested as described above.

- 57 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:	Rao, Anjana Hogan, Patrick Gerald McCaffrey, Patricia Jain, Jugnu
(ii) TITLE OF INVENTION:	NF-ATP, A T LYMPHOCYTE DNA-BINDING PROTEIN
(iii) NUMBER OF SEQUENCES:	22
(iv) CORRESPONDENCE ADDRESS:	
(A) ADDRESSEE:	Fish & Richardson
(B) STREET:	225 Franklin Street
(C) CITY:	Boston
(D) STATE:	Massachusetts
(E) COUNTRY:	U.S.A.
(F) ZIP:	02110-2804
(v) COMPUTER READABLE FORM:	
(A) MEDIUM TYPE:	3.5" Diskette, 1.44 Mb
(B) COMPUTER:	IBM PS/2 Model 50Z or 55SX
(C) OPERATING SYSTEM:	MS-DOS (Version 5.0)
(D) SOFTWARE:	WordPerfect (Version 5.1)
(vi) CURRENT APPLICATION DATA:	
(A) APPLICATION NUMBER:	08/145,006
(B) FILING DATE:	October 29, 1993
(C) CLASSIFICATION:	
(vii) PRIOR APPLICATION DATA:	
(A) APPLICATION NUMBER:	08/017,052
(B) FILING DATE:	February 11, 1993
(A) APPLICATION NUMBER:	08/006,067
(B) FILING DATE:	January 15, 1993
(viii) ATTORNEY/AGENT INFORMATION:	
(A) NAME:	Fraser, Janis K.
(B) REGISTRATION NUMBER:	34,819
(C) REFERENCE/DOCKET NUMBER:	04590/007001
(ix) TELECOMMUNICATION INFORMATION:	
(A) TELEPHONE:	(617) 542-5070
(B) TELEFAX:	(617) 542-8906
(C) TELEX:	200154

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	29
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single

- 58 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GCCCAAAGAG GAAAATTTGT TTCATACAG 29

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GCCCAAAGAG GAAAATTTGT TTATATCAG 29

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCCCAAAGAG GAAAATGGAC TTCATACAG 29

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCCCAAAGAC CTTAATTTGT TTCATACAG 29

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 890
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Gly Ser Ser Ala Ser Phe Ile Ser Asp Thr Phe Ser Pro Tyr Thr Ser
1 5 10 15

- 59 -

Pro	Cys	Val	Ser	Pro	Asn	Asn	Ala	Gly	Pro	Asp	Asp	Leu	Cys	Pro	Gln
20							25					30			
Phe	Gln	Asn	Ile	Pro	Ala	His	Tyr	Ser	Pro	Arg	Thr	Ser	Pro	Ile	Met
35							40					45			
Ser	Pro	Arg	Thr	Ser	Leu	Ala	Glu	Asp	Ser	Cys	Leu	Gly	Arg	His	Ser
50							55					60			
Pro	Val	Pro	Arg	Pro	Ala	Ser	Arg	Ser	Ser	Pro	Gly	Ala	Lys	Arg	
65							70					75			80
Arg	His	Ser	Cys	Ala	Glu	Ala	Leu	Val	Ala	Pro	Leu	Pro	Ala	Ala	Ser
85							90					95			
Pro	Gln	Arg	Ser	Arg	Ser	Pro	Ser	Pro	Gln	Pro	Ser	Pro	His	Val	Ala
100							105					110			
Pro	Gln	Asp	Asp	Ser	Ile	Pro	Ala	Gly	Tyr	Pro	Pro	Thr	Ala	Gly	Ser
115							120					125			
Ala	Val	Leu	Met	Asp	Ala	Leu	Asn	Thr	Leu	Ala	Thr	Asp	Ser	Pro	Cys
130							135					140			
Gly	Ile	Pro	Ser	Lys	Ile	Trp	Lys	Thr	Ser	Pro	Asp	Pro	Thr	Pro	Val
145							150					155			160
Ser	Thr	Ala	Pro	Ser	Lys	Ala	Gly	Leu	Ala	Arg	His	Ile	Tyr	Pro	Thr
165							170					175			
Val	Glu	Phe	Leu	Gly	Pro	Cys	Glu	Gln	Glu	Glu	Arg	Arg	Asn	Ser	Ala
180							185					190			
Pro	Glu	Ser	Ile	Leu	Leu	Val	Pro	Pro	Thr	Trp	Pro	Lys	Gln	Leu	Val
195							200					205			
Pro	Ala	Ile	Pro	Ile	Cys	Ser	Ile	Pro	Val	Thr	Ala	Ser	Leu	Pro	Pro
210							215					220			
Leu	Glu	Trp	Pro	Leu	Ser	Asn	Gln	Ser	Gly	Ser	Tyr	Glu	Leu	Arg	Ile
225							230					235			240
Glu	Val	Gln	Pro	Lys	Pro	His	His	Arg	Ala	His	Tyr	Glu	Thr	Glu	Gly
245							250					255			
Ser	Arg	Gly	Ala	Val	Lys	Ala	Pro	Thr	Gly	Gly	His	Pro	Val	Val	Gln
260							265					270			
Leu	His	Gly	Tyr	Met	Glu	Asn	Lys	Pro	Leu	Gly	Leu	Gln	Ile	Phe	Ile
275							280					285			
Gly	Thr	Ala	Asp	Glu	Arg	Ile	Leu	Lys	Pro	His	Ala	Phe	Tyr	Gln	Val
290							295					300			
His	Arg	Ile	Thr	Gly	Lys	Thr	Val	Thr	Thr	Ser	Tyr	Glu	Lys	Ile	
305							310					315			320
Val	Gly	Asn	Thr	Lys	Val	Leu	Glu	Ile	Pro	Leu	Glu	Pro	Lys	Asn	Asn
325							330					335			
Met	Arg	Ala	Thr	Ile	Asp	Cys	Ala	Gly	Ile	Leu	Lys	Leu	Arg	Asn	Ala
340							345					350			

- 60 -

Asp Ile Leu Arg Lys Gly Glu Thr Asp Ile Gly Arg Lys Asn Thr
 355 360 365
 Arg Val Arg Leu Val Phe Arg Val His Val Pro Glu Pro Ser Gly Arg
 370 375 380
 Ile Val Ser Leu Gln Ala Ala Ser Asn Pro Ile Glu Cys Ser Gln Arg
 385 390 395 400
 Ser Ala His Glu Leu Pro Met Val Glu Arg Gln Asp Met Asp Ser Cys
 405 410 415
 Leu Val Tyr Gly Gly Gln Gln Met Ile Leu Thr Gly Gln Asn Phe Thr
 420 425 430
 Ala Glu Ser Lys Val Val Phe Met Glu Lys Thr Thr Asp Gly Gln Gln
 435 440 445
 Ile Trp Glu Met Glu Ala Thr Val Asp Lys Asp Lys Ser Gln Pro Asn
 450 455 460
 Met Leu Phe Val Glu Ile Pro Glu Tyr Arg Asn Lys His Ile Arg Val
 465 470 475 480
 Pro Val Lys Val Asn Phe Tyr Val Ile Asn Gly Lys Arg Lys Arg Ser
 485 490 495
 Gln Pro Gln His Phe Thr Tyr His Pro Val Pro Ala Ile Lys Thr Glu
 500 505 510
 Pro Ser Asp Glu Tyr Glu Pro Ser Leu Ile Cys Ser Pro Ala His Gly
 515 520 525
 Gly Leu Gly Ser Gln Pro Tyr Tyr Pro Gln His Pro Met Leu Ala Glu
 530 535 540
 Ser Pro Ser Cys Leu Val Ala Thr Met Ala Pro Cys Gln Gln Phe Arg
 545 550 555 560
 Ser Gly Leu Ser Ser Pro Asp Ala Arg Tyr Gln Gln Gln Ser Pro Ala
 565 570 575
 Ala Ala Leu Tyr Gln Arg Ser Lys Ser Leu Ser Pro Gly Leu Leu Gly
 580 585 590
 Tyr Gln Gln Pro Ser Leu Leu Ala Ala Pro Leu Gly Leu Ala Asp Ala
 595 600 605
 His Arg Ser Val Leu Val His Ala Gly Ser Gln Gly Gln Gly Gln Gly
 610 615 620
 Ser Thr Leu Arg His Thr Ser Ser Ala Ser Gln Gln Ala Ser Pro Val
 625 630 635 640
 Ile His Tyr Ser Pro Thr Asn Gln Gln Leu Arg Gly Gly Gly His Gln
 645 650 655
 Glu Phe Gln His Ile Met Tyr Cys Glu Asn Phe Gly Pro Ser Ser Ala
 660 665 670
 Arg Pro Gly Pro Pro Pro Ile Asn Gln Gly Gln Arg Leu Ser Pro Gly
 675 680 685

- 61 -

Ala Tyr Pro Thr Val Ile Gln Gln Gln Thr Ala Pro Ser Gln Arg Ala
 690 695 700
 Ala Lys Asn Gly Pro Ser Asp Gln Lys Glu Ala Leu Pro Thr Gly Val
 705 710 715 720
 Thr Val Lys Gln Glu Gln Asn Leu Asp Gln Thr Tyr Leu Asp Asp Ala
 725 730 735
 Ala Thr Ser Glu Ser Trp Val Gly Thr Glu Arg Tyr Ile Glu Arg Lys
 740 745 750
 Phe Trp Lys Lys Thr Leu Val Gln Pro Gly Leu Leu Pro Ser Phe Leu
 755 760 765
 Leu Leu Gly Ser Leu Ser Ala Gly Pro Arg Ser Gln Thr Pro Ser Glu
 770 775 780
 Arg Lys Pro Ile Glu Glu Asp Val Pro Leu Ser Cys Ser Gln Ile Ala
 785 790 795 800
 Trp Cys Cys Gln His Pro Leu Gly Thr Cys Pro Val Leu Pro Gly Pro
 805 810 815
 Leu Ala Val Glu Trp Trp Glu Gly Gln Leu Gly Arg Gly Leu Glu Pro
 820 825 830
 Ile Pro Trp Ala Pro Asp Ser Ala Gly Ser Leu His Glu Val Asp Ser
 835 840 845
 Val Gly Leu Ala Gly Val Val Gly Met Val Leu Leu Thr Leu Met His
 850 855 860
 His Phe Ser Met Asp Gln Asn Gln Thr Pro Ser Pro His Trp Gln Arg
 865 870 875 880
 His Lys Glu Val Ala Ser Pro Gly Trp Ile
 885 890

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Arg Gly Ser His His His His His His Thr Ala Pro His Ala Ser
 1 5 10 15

Ser Val

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9

- 62 -

(B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Val Asp Leu Glu Pro Ser Leu Ile Ser
 1 5

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 732
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GCGGCTCCCTC TGCCAGCTTC ATTTCTGACA CCTTCTCCCC CTACACCTCG CCCTGCGTCT	60
CACCCAATAA CGCCGGGCC GACGACCTGT GTCCCCAGTT TCAAAACATC CCTGCTCATT	120
ATTCCCCCAG AACCTCTCCA ATAATGTCAC CTCGAACCAG CCTCGCCGAG GACAGCTGCC	180
TGGGGCGACA CTCGCCCCGTG CCCC GTCCGG CATCCCGCTC CTCCCTCACCC GGTGCCAAGC	240
GGAGGCATTC GTGCGCAGAG GCTTTGGTTG CTCCCTGCTC CGCAGCCTCA CCCCAGCGCT	300
CCCGGAGCCC CTCGCCACAG CCCTCGCCTC ACGTGGCACC GCAGGACGAC AGCATCCCCG	360
 CTGGGTACCC CCCCACGGCC GGCTCTGCTG TTCTCATGGA TGCCCTCAAC ACCCTGGCCA	420
CCGACTCGCC CTGCGGGATC CCCTCCAAGA TATGGAAGAC CAGTCCTGAC CCGACGCCCTG	480
TGTCCACCGC TCCGTCCAAG GCTGGCTGG CCCGCCACAT CTACCCCTACT GTGGAGTTCC	540
TGGGGCCATG TGAGCAGGAG GAGAGGAGGA ATTCCGCTCC AGAGTCCATC CTGCTGGTAC	600
CACCTACTTG GCCCAAGCAG TTGGTGCCGG CCATTCCCAT CTGCAGCATC CCTGTGACTG	660
CATCCCTCCC ACCACTCGAG TGGCCACTCT CCAATCAGTC GGGCTCCTAT GAGCTACGGA	720
TTGAGGTCCA AC	732

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CGTTCGGATC CAGTGTYYAT GGAGAACACT ACA 33

- 63 -

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	34
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

CGACAGGAT CCTGYTGNATN ACNGTNGGRT ANGC 34

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	432
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CCCGGAGCCC CTCGCCGCAG CCCTCATCTC ACGTGGCACCC AGGACCAC GGCTCCCCGG	60
CTGGGTACCC CCCTGTGGCT GGCTCTGCCG TGATCATGGA TGCCCTGAAC AGCCTCGCCA	120
CGGACTCGCC TTGTGGNATC CCCCCCCAAGA TGTGGAAGAC CAGCCCTGAC CCCTCGCCGG	180
TGTCTCGCGC CCCATCCAAG GCNGGCCTGC CTCGCCACAT CTACCCGCC GTGGAGTTCC	240
TGGGGCNTG CGAGCAGGGC GAGAGGAGAA ACTCGGCTCC AGAATCCATC CTGCTGGTTC	300
CGCCCACTTG NCCCAAGCCG CTGGTGCCTG CCATTCCAT CTCGACGATC CCATGAGCTC	360
GATCCCTCCC TNCACTTGAG TGGCCGCTGT CCAGTCAGTC ATCGCGTTAC GAGCTGCGGA	420
TCGAGGTGCA GC	432

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	357
(B) TYPE:	amino acid
(C) STRANDEDNESS:	
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Ala Tyr Pro Asp Asp Val Leu Asp Tyr Gly Leu Lys Pro Tyr Ser Pro	
1 5 10 15	
Leu Ala Ser Leu Ser Gly Glu Pro Pro Gly Arg Phe Gly Glu Pro Asp	
20 25 30	
Arg Val Gly Pro Gln Lys Phe Leu Ser Ala Ala Lys Pro Ala Gly Ala	
35 40 45	

- 64 -

Ser	Gly	Leu	Ser	Pro	Arg	Ile	Glu	Ile	Thr	Pro	Ser	His	Glu	Leu	Ile
50						55						60			
Gln	Ala	Val	Gly	Pro	Leu	Arg	Met	Arg	Asp	Ala	Gly	Leu	Leu	Val	Glu
65						70					75			80	
Gln	Pro	Pro	Leu	Ala	Gly	Val	Ala	Ala	Ser	Pro	Arg	Phe	Thr	Leu	Pro
											90			95	
Val	Pro	Gly	Phe	Glu	Gly	Tyr	Arg	Gln	Pro	Leu	Cys	Leu	Ser	Pro	Ala
						100				105			110		
Ser	Ser	Gly	Ser	Ser	Ala	Ser	Phe	Ile	Ser	Asp	Thr	Phe	Ser	Pro	Tyr
								115		120			125		
Thr	Cys	Pro	Cys	Val	Ser	Pro	Asn	Asn	Gly	Gly	Pro	Asp	Asp	Leu	Cys
							130		135			140			
Pro	Gln	Phe	Gln	Asn	Ile	Pro	Ala	His	Tyr	Ser	Pro	Arg	Thr	Ser	Pro
145						150			155			160			
Ile	Met	Ser	Pro	Arg	Thr	Ser	Leu	Ala	Glu	Asp	Ser	Cys	Leu	Gly	Arg
						165			170			175			
His	Ser	Pro	Val	Pro	Arg	Pro	Ala	Ser	Arg	Ser	Ser	Ser	Pro	Gly	Ala
						180			185			190			
Lys	Arg	Arg	His	Ser	Cys	Ala	Glu	Ala	Leu	Val	Ala	Leu	Pro	Pro	Gly
						195			200			205			
Ala	Ser	Pro	Gln	Arg	Ser	Arg	Ser	Pro	Ser	Pro	Gln	Pro	Ser	Ser	His
						210			215			220			
Val	Ala	Pro	Gln	Asp	His	Gly	Ser	Pro	Ala	Gly	Tyr	Pro	Pro	Val	Ala
225						230				235			240		
Gly	Ser	Ala	Val	Ile	Met	Asp	Ala	Leu	Asn	Ser	Leu	Ala	Thr	Asp	Ser
						245			250			255			
Pro	Cys	Gly	Ile	Pro	Pro	Lys	Met	Trp	Lys	Thr	Ser	Pro	Asp	Pro	Ser
						260			265			270			
Pro	Val	Ser	Arg	Ala	Pro	Ser	Lys	Ala	Gly	Leu	Pro	Arg	His	Ile	Tyr
						275			280			285			
Pro	Ala	Val	Glu	Phe	Leu	Gly	Pro	Cys	Glu	Gln	Gly	Glu	Arg	Arg	Asn
						290			295			300			
Ser	Ala	Pro	Glu	Ser	Ile	Leu	Leu	Val	Pro	Pro	Thr	Trp	Pro	Lys	Pro
305						310				315			320		
Leu	Val	Pro	Ala	Ile	Pro	Ile	Ser	Thr	Ile	Pro	Xaa	Ala	Arg	Ser	Leu
						325			330			335			
Pro	Pro	Leu	Glu	Trp	Pro	Leu	Ser	Ser	Gln	Ser	Ser	Arg	Tyr	Glu	Leu
						340			345			350			
Arg	Ile	Glu	Val	Gln											
						355									

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 13:

- 65 -

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	60
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GGATGACCGCA CCCACTTCAG AAAGCTGGGT TGGGACAGAA AGGTATATAG AGAGAAAAATT 60

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	52
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

GGATGACGAG TTGATAGACA CACACCTTAG CTGGATACAA AACATATTAT GA 52

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	60
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GGATGACGTT AATGAAATCA TCAGGAAGGA GTTTTCAGGA CCTCCCTCCC GAAATCAGAC 60

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	16
(B) TYPE:	amino acid
(C) STRANDEDNESS:	
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Asp Asp Ala Ala Thr Ser Glu Ser Trp Val Gly Thr Glu Arg Tyr Ile
1 5 10 15

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	16
(B) TYPE:	amino acid
(C) STRANDEDNESS:	
(D) TOPOLOGY:	linear

- 66 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Asp	Asp	Glu	Leu	Ile	Asp	Thr	His	Leu	Ser	Trp	Ile	Gln	Asn	Ile	Leu
1				5					10			15			

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 18:

(i) SEQUENCE CHARACTERISTICS:

- | | |
|-------------------|------------|
| (A) LENGTH: | 20 |
| (B) TYPE: | amino acid |
| (C) STRANDEDNESS: | |
| (D) TOPOLOGY: | linear |

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Asp	Asp	Val	Asn	Glu	Ile	Ile	Arg	Lys	Glu	Phe	Ser	Gly	Pro	Pro	Ser
1				5					10			15			

Arg	Asn	Gln	Thr
		20	

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 19:

(i) SEQUENCE CHARACTERISTICS:

- | | |
|-------------------|--------------|
| (A) LENGTH: | 1474 |
| (B) TYPE: | nucleic acid |
| (C) STRANDEDNESS: | double |
| (D) TOPOLOGY: | linear |

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

AGCAGGAAGC	TCGCGCCGCC	GTCGCCGCCG	CCGCTCAGCT	TCCCCGGCG	CGTCCAGGAC	60
CCGCTGCGCC	AGGCGCGCCG	TCCCCGGACC	CGGC GTGCGT	CCCTACGAGG	AARGGGACCC	120
CGCCGCTCGA	GCCGCCTCCG	CCAGCCCCAC	TGCGAGGGGT	CCCAGAGCCA	GCCGCGCCCG	180
CCCTCGCCCC	CGGCCCCCGCA	GCCTTCCCGC	CCTGCGCGCC	ATGAACGCCC	CCGAGCGGCA	240
GCCCCAACCC	GACGGCGGGG	ACGCCCCAGG	CCACGAGCCT	GGGGGCAGCC	CCCAAGACGA	300
GCTTGACTTC	TCCATCCTCT	TCGACTATGA	GTATTTGAAT	CCGAACGAAG	AAGAGCCGAA	360
TGCACATAAG	GTCGCCAGCC	CACCCCTCCGG	ACCCGCATAC	CCCGATGATG	TCCTGGACTA	420
TGGCCTCAAG	CCATACAGCC	CCCTTGCTAG	TCTCTCTGGC	GAGCCCCCG	GCCGATT CGG	480
AGAGCCGGAT	AGGGTAGGGC	CGCAGAAAGTT	TCTGAGCGCC	GCCAAGCCAG	CAGGGGCCTC	540
GGGCTGAGC	CCTCGGATCG	AGATCACTCC	GTCCCACGAA	CTGATCCAGG	CAGTGGGGCC	600
CCTCCGCATG	AGAGACGCGG	GCCTCCTGGT	GGAGCAGCCG	CCCCTGGCCG	GGGTGGCCGC	660
CAGCCCCGAGG	TTCACCCCTGC	CCGTGCCCGG	CTTCGAGGGC	TACCGCGAGC	CGCTTTGCTT	720
GAGCCCCGCT	AGCAGCGGCT	CCTCTGCCAG	CTTCATTTCT	GACACCTTCT	CCCCCTACAC	780
CTCGCCCTGC	GTCTCGCCCA	ATAACGGCGG	GCCCCGACGAC	CTGTGTCCGC	AGTTTCAAAA	840

- 67 -

CATCCCTGCT CATTATTCCC CCAGAACCTC GCCAATAATG TCACCTCGAA CCAGCCTCGC	900
CGAGGACAGC TGCCTGGGCC GCCACTCGCC CGTGCCCCGT CGGGCCTCCC GCTCCTCATC	960
GCCTGGTGCC AAGCGGAGGC ATTCGTGCGC CGAGGCCTTG GTTGCCTGCG CGCCCGGAGC	1020
CTCACCCAG CGCTCCCGGA GCCCCTCGCC GCAGCCCTCA TCTCACGTGG CACCCAGGA	1080
CCACGGCTCC CGGGCTGGGT ACCCCCCCTGT GGCTGGCTCT GCCGTGATCA TGGATGCCCT	1140
GAACAGCCTC GCCACGGACT CGCCTTGTGG GATCCCCCCC AAGATGTGGA AGACCAGCCC	1200
TGACCCCTCG CCGGTGTCTG CCGCCCCATC CAAGGCCGGC CTGCCTCGCC ACATCTACCC	1260
GGCCGTGGAG TTCCTGGGGC CCTGCGAGCA GGGCGAGAGG AGAAAATCGG CTCCAGAAC	1320
CATCCCTGCTG GTTCCGCCCCA CTTGGCCCAA ACCGCTGGTG CCTGCCATTC CCATCTGCAG	1380
CATCCCAGTG ACTGCATCCC TCCCTCCACT TGAGTGGCCG CTGTCCAGTC AGTCAGGCTC	1440
TTACGAGCTG CGGATCGAGG TCCAGCCTCG TGCC	1474

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	2675
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

GCGGCTCTC TGCCAGCTTC ATTCTGACA CCTTCTCCCG CTACACCTCG CCCTGCGTCT	60
CACCAATAA CGCCGGGCC GACGACCTGT GTCCCCAGTT TCAAAACATC CCTGCTCATT	120
ATTCCCCAG AACCTCTCCA ATAATGTCAC CTCGAACCAAG CCTCGCCGAG GACAGCTGCC	180
TGGGGCGACA CTCGCCCCGTG CCCCGTCCGG CATCCCGCTC CTCCCTCACCC GGTGCCAAGC	240
GGAGGCATTC GTGCGCAGAG GCTTTGGTTG CTCCCTTGCC CGCAGCCTCA CCCCAGCGCT	300
CCCGGAGCCC CTCGCCACAG CCCTGCCCTC ACCTGGCACC GCAGGACGCC AGCATCCCCG	360
CTGGGTACCC CCCCACGGCC GGCTCTGCTG TTCTCATGGA TGCCCTCAAC ACCCTGGCCA	420
CCGACTCGCC CTGCGGGATC CCCTCCAAGA TATGGAAGAC CAGTCCTGAC CCGACGCCCTG	480
TGTCCACCGC TCCGTCCAAG GCTGGCCTGG CCCGCCACAT CTACCCCTACT GTGGAGTTCC	540
TGGGGCCATG TGAGCAGGAG GAGAGGAGGA ATTCGCTCC AGAGTCCATC CTGCTGGTAC	600
CACCTACTTG GCCCAAGCAG TTGGTGCCGG CCATTCCCAT CTGCAGCATE CCTGTGACTG	660
CATCCCTCCC ACCACTCGAG TGGCCACTCT CCAATCAGTC GGGCTCCTAT GAGCTACGGA	720
TTGAGGTCCA ACCCAAGCCC CATCACCGGG CCCACTATGA GACGGAGGGC AGCCGTGGCG	780
CTGTCAAAGC CCCAACAGGA GGACACCCCTG TGGTGCAGCT CCACGGCTAC ATGGAGAAC	840
AGCCTCTGGG GCTTCAGATC TTCATTGGGA CAGCAGATGA GAGGATCCTT AAGCCGCACG	900

- 68 -

CCTTCTACCA AGTACACAGG ATCACTGGGA AAACGGTCAC CACCACGAGC TATGAGAAGA 960
TCGTAGGCAA CACCAAGGTC CTGGAGATCC CCCTGGAGCC AAAGAACAAAC ATGAGAGCCA 1020
CCATCGACTG TGCAGGCATC CTGAAGCTCC GAAACGCTGA CATCGAGCTG CGGAAGGGCG 1080
AGACGGACAT CGGCAGGAAG AACACCGCTG TGCGCCTGGT GTTCCGCGTG CACGTCCCAG 1140
AGCCCCAGTGG CGGCATCGTC TCCCTGCAGG CTGCGTCCAA CCCCATCGAG TGCTCTCAGC 1200
GCTCTGCCA CGAGCTGCC ATGGTGGAGA GACAAGACAT GGACAGCTGC CTGGTCTACG 1260
GGGGCCAGCA GATGATCCTC ACGGGCCAGA ACTTCACAGC GGAGTCCAAG GTTGTGTTCA 1320
TGGAGAAAGAC TACAGATGGG CAGCAGATTT GGGAGATGGA AGCTACGGTG GATAAAGACA 1380
AGAGCCAGCC TAACATGCTT TTTGTTGAGA TCCCCGAGTA TCGGAACAAG CACATCCGCG 1440
TGCCCCTGAA AGTCAACTTC TACGTCTAC ACGGAAAGAG GAAACGAAGT CAGCCACAGC 1500
ACTTTACCTA CCACCCAGTC CCTGCCATCA AGACAGAGCC CAGCGATGAG TATGAACCAT 1560
CTTGATCTG CAGCCCCGCC CATGGAGGCC TGAGGAGCCA GCCATATTAC CCACAGCACC 1620
CAATGCTGGC CGAGTCCCCC TCCTGCCCTG TGCTTACCAT GGCCCCCTGC CAACAGTTCC 1680
GCTCGGGGCT CTCATCCCCC GATGCTCGCT ACCAACAGCA GAGCCCCGCA GCTGCCCTCT 1740
ACCAGAGAAAG CAAGAGCCTG AGTCCCGGCC TGCTGGGCTA CCAGCAGCCG TCCCTCCTGG 1800
CAGCACCCCTT GGGTCTGGCT GATGCCACC GCTCTGTGCT GGTGCATGCT GTTCTCAGG 1860
GGCAGGGGCA GGGCTCCACC CTCCGACACA CATCCTCGGC CAGCCAGCAG GCCTCACCCG 1920
TGATCCACTA CTCACCCACC AACCAAGCAGC TTGCGGGTGG GGGTCACCCAG GAGTCCAGC 1980
ATATCATGTA CTGTAAAAAC TTCGGCCCCA GCTCTGCCAG GCCTGGCCCG CCTCCCATCA 2040
ACCAAGGTCA GAGGCTGAGC CCGGGCGCCT ACCCCACAGT CATCCACAA CAGACTGCC 2100
CGAGCCAAAG AGCTGCCAAA AACGGACCCA GTGACCAGAA GGAAGCTCTG CCCACGGGAG 2160
TGACCGTCAA ACAGGAACAG AACCTGGACC AGACCTACCT GGATGACGCA GCCACTTCAG 2220
AAAGCTGGGT TGGGACAGAA AGGTATATAG AGAGAAAATT TTGGAAGAAG ACCCTTGTGC 2280
AGCCTGGGCT CCTGCCCTCA TTTTACTTC TTGGCTCCCT GTCTGCTGGA CCAAGGTAC 2340
AGACACCATC AGAAAGAAAG CCCATAGAGG ARGACGTGCC CTTGAGTTGC AGCCAGATAG 2400
CCTGGTGTG TCAGCATCCC TTGGGGACCT GCCCTGTCCCT GCCAGGGCCT TTAGCTGTAG 2460
AGTGGTGGGA AGGGCAGCTC GGGCGTGGGC TGGAGCCAAT TCCCTGGGCT CCAGACAGTG 2520
CCGGCAGCCT CCATGAGGTG GACAGTGTAG GCCTGGCGGG AGTGGTGGGA ATGGTTCTGC 2580
TCACTCTTAT GCACCACTTC TCCATGGATC AGAACCCAGAC CCCCTCTCCT CACTGGCAAA 2640
GGCACAAAGA GGTTGCTAGC CCAGGCTGGA TCTGA 2675

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 21:

- 69 -

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	113
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

ATGGGCTCAT CAACTTCATC AAGCAGCGAG GCGAGGCCAG AGTCCAATAA ACTCGTGCTC	60
ATCTGCAGCC TCCTCTGTGA CTCCCCCTCT CTTCTAGTCC CTCCCTCCGG AGC	113

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	732
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GCGGCTCCTC TGCCAGCTTC ATTTCTGACA CCTTCTCCCC CTACACCTGC CCCTGCGTCT	60
CGCCCAATAA CGGCGGGCCC GACGACCTGT GTCCGCAGTT TCAAAACATC CCTGCTCATT	120
ATTCCCCCAG AACCTCGCCA ATAATGTCAC CTCGAACCAG CNTCGCCGAG GACAGCTGCC	180
TGGGGCCGCA CTCGCCCCGTG CCCCGTCCGG CCTCCCGCTC CTCATCGCCT GGTGCCAAGC	240
GGAGGCATTC GTGCGCCGAG GCCTTGGTTG CCCTGCCGCC CGGAGCCTCA CCCCAGCGCT	300
CCCGGAGCCC CTCGCCGCAG CCCTCATCTC ACGTGGCACCC AGGACCAC GGCTCCCCGG	360
CTGGGTACCC CCCTGTGGCT GGCTCTGCTG TGATCATGGA TGCCCTGAAC AGCCTCGCCA	420
CGGACTCGCC TTGTGGNATC CCCCCCAAGA TGTTGGAAAGAC CAGTCCTGAC CCCTCGCCGG	480
TGTCTCGCGC CCCATCCAAG GCNGGCCTGC CTCGCCACAT CTACCCGCC GTGGAGTTCC	540
TGGGGCANTG CGAGCAGGGC GAGAGGAGAA ACTCGGCTCC AGAATCCATC CTGCTGGTTC	600
CGCCCACTTG NCCCAAGCCG CTGGTGCCTG CCATTCCCAT CTCGACGATC CCATGAGCTC	660
GATCCCTCCC TNCACTTGAG TGGCCGCTGT CCAGTCAGTC ATCGCGTTAC GAGCTGCGGA	720
TCGAGGTGCA GC	732

- 70 -

What is claimed is:

- 71 -

1. A purified preparation of NF-AT_p protein.
2. The preparation of claim 1, wherein said NF-AT_p is human NF-AT_p.
3. The preparation of claim 1, wherein said NF-AT_p is phosphorylated.
4. The preparation of claim 1, wherein said NF-AT_p is not phosphorylated.
5. An isolated DNA encoding NF-AT_p.
6. The isolated DNA of claim 5, wherein said DNA encodes human NF-AT_p.
7. The isolated DNA of claim 5, wherein said DNA encodes murine NF-AT_p.
8. A cell containing the isolated DNA of claim 5.
9. A method of manufacturing NF-AT_p, comprising culturing the cell of claim 8 under conditions permitting the expression of said DNA.
10. A purified preparation of NF-AT_p complexed with Fos protein.
11. A purified preparation of NF-AT_p complexed with Jun protein.
12. A purified preparation of NF-AT_p complexed with both Fos and Jun proteins.
13. An antibody which binds to an epitope of NF-AT_p.

- 72 -

14. The antibody of claim 13, wherein said antibody is a monoclonal antibody.

15. A method for detecting expression of NF-AT_p in a cell, which method comprises
contacting proteins of said cell with the antibody of claim 13, and
detecting immune complex formation.

16. A method for detecting expression of NF-AT_p in a cell, which method comprises
contacting the mRNA of said cell with a hybridization probe comprising a 20 nucleotide, single-stranded segment of the isolated DNA of claim 5, and
detecting hybridization of said probe with said mRNA.

17. A method for screening potential immunosuppressive agents, which method comprises
providing purified, phosphorylated NF-AT_p;
contacting said NF-AT_p with calcineurin in the presence of a candidate immunosuppressive compound; and
determining whether dephosphorylation of NF-AT_p by calcineurin is inhibited by said candidate compound.

18. A method for screening potential immunosuppressive agents, which method comprises
providing purified NF-AT_p;
contacting said NF-AT_p, in the presence of a candidate immunosuppressive compound, with an oligonucleotide comprising a sequence substantially identical to GCCCAAAGAGGAAAATTGTTTCATACAG (SEQ ID NO:1);
and
determining whether said candidate compound inhibits binding of said oligonucleotide to said NF-AT_p.

- 73 -

19. A method for screening potential immunosuppressive agents, which method comprises

providing purified NF-AT_p;

contacting said NF-AT_p with Fos, in the presence of a candidate immunosuppressive compound; and

determining whether said candidate compound inhibits binding of said Fos to said NF-AT_p.

20. A method for screening potential immunosuppressive agents, which method comprises

providing purified NF-AT_p;

contacting said NF-AT_p with Jun, in the presence of a candidate immunosuppressive compound; and

determining whether said candidate compound inhibits binding of said Jun to said NF-AT_p.

21. A method for screening potential immunosuppressant agents, which method comprises;

providing a purified or partially purified NF-AT_p protein or peptide;

contacting said NF-AT_p protein or peptide with a candidate compound obtained from a protein or peptide library or a library of organic or inorganic compounds;

determining whether the candidate compound binds to said NF-AT_p protein or peptide, wherein binding of said candidate compound to said NF-AT_p protein or peptide is an indication that said candidate compound may have immunosuppressant activity; and then

screening candidate compounds which bind to said NF-AT_p protein or peptide in any one of the methods of claims 17 - 20.

22. An isolated DNA encoding nuclear factor of activated T cells (NF-AT_p).

- 74 -

23. A vector comprising the isolated DNA of claim 1.

23. The isolated DNA of claim 1, wherein said DNA encodes human NF-AT_p.

24. The isolated DNA of claim 1, wherein said DNA encodes murine NF-AT_p.

25. A cell containing the isolated DNA of claim 1.

26. The isolated DNA of claim 1, wherein said DNA encodes a protein which comprises the amino acid sequence of SEQ ID NO:5.

27. The isolated DNA of claim 1, wherein said DNA encodes a protein which comprises the amino acid sequence of SEQ ID NO:12.

28. An isolated DNA comprising Fig. 22 (SEQ ID NO:21).

29. An isolated DNA comprising the DNA of Fig. 17 (SEQ ID NO:11), Fig. 21 (SEQ ID NO:19) or Fig. 23 (SEQ ID NO:20).

30. A method of manufacturing NF-AT_p, comprising culturing the cell of claim 4 under conditions permitting the expression of said DNA.

31. An isolated DNA comprising a 20 nucleotide segment of Fig. 22 (SEQ ID NO:21).

32. An isolated DNA comprising a 20 nucleotide segment of Fig. 17 (SEQ ID NO:11), Fig. 21 (SEQ ID NO:19) or Fig. 23 (SEQ ID NO:20).

- 75 -

33. A method for detecting expression of NF-AT_p in a cell, which method comprises

contacting the mRNA of said cell with a hybridization probe comprising a 20 nucleotide, single-stranded segment of the isolated DNA of claim 1, and detecting hybridization of said probe with said mRNA.

34. An isolated DNA comprising 20 nucleotides, wherein a strand of said DNA hybridizes under stringent conditions to a strand of a DNA encoding NF-AT_p.

35. An isolated DNA which encodes a segment of NF-AT_p which binds Fos-Jun or Jun-Jun.






FIG. 1






FIG. 3




FIG. 4A





FIG. 4B



Untreated
FIG. 5A



CsA
FIG. 5B



Mixed
FIG. 5C



143,126 k_L
126,112,
100,112,

Control peptide 

Inhibitory peptide 

FIG. 6




FIG. 7




FIG. 8




FIG. 9

8/21

1 GSSASFISDTFSYTSPCVSPNNAGPDDLCQFQNIPAH.SPRTSPIMSP

51 RTSLAEDSCLGRHSPVPRPASRSSSPGAKRRHSCAEALVAPLPAASPQRS

101 RSPSPQPSPHVAPQDDSIIPAGYPPTAGSAVLMDALNTLATDPCGIPSKI

151 WKTSPDPTPVSTAPSKAGLARHIYPTVEFLGPCEQEERRNSAPESILLVP
 x-23.3-

201 PTWPKQLVPAIPICSIPVTASLPPLWEWPLSNQSGSYELRIEVQPKPHRA
 72 x

251 HYETEGSRGAVKAPTGGHPVVQLHGYMENKPLGLQIFIGTADERILKPHA

301 FYQVHRITGKTVTTSYEKIVGNTKVLEIIPLEPKNNMRATIDCAGILKLR

351 NADIELRKGETDIGRKNTRVRLVFRHVPEPSGRIVSLQAASNPIECSQR

401 SAHELPMVERQDMDSCLVYGGQQMILTQNFTAESKVVFMEKTTDGQQIW
 48 23.2

451 EMEATVDKDKSQPNMLFVEIPEYRNKHIRVPVKVNFYVINGKRKRSQPQH

501 FTYHPVPAIKTEPSDEYEPSLICSPAHLGLGSQPYQPQHMLAESPSCLV

551 ATMAPCQQFRSGLSSPDARYQQQSPAAALYQRSKSLSPGLLGYQQPSLLA
 10.1 23.1

601 APLGLADAHRSQLVHAGSQGQGQGSTLRHTSSASQQASPVITHYSPTNQL

651 RGGGHQEFAQHIMYCENFGPSSARPGPPPINQGQRILSPGAYPTVIQQQTAP
 25

701 SQRAAKNGPSDQKEALPTGVTVKQEQNLDQTYLDDAATSESWVGTERYIE

751 RFWKKTLVQPGLLPSFLLGSLSAGPRSQTPSERKPIEEDVPLSCSQIA

801 WCCQHPLGTCVPVLPGPLAVEWWEGQLGRGLEPIPWAPDSAGSLHEVDSVG

851 LAGVVMVLLTLMHHFSMDQNQTPSPHWQRHKEVASPGWI@ SEQ ID NO: 5

FIG. 10




FIG. 11

FIG. 12




FIG. 13

11/21




FIG. 14




FIG. 15




FIG. 16

-----	GCATAACCCG	ATGATGTCCT	GGACTATGGC	CTCAAGCCAT	40
ACAGCCCCCT	TGCTAGTCTC	TCTGGCGAGC	CCCCCGGCCG	ATTGGAGAG	
CCGGATAGGG	TAGGGCCGCA	GAAGTTTCTG	AGCGCGGCCA	AGCCAGCAGG	140
GGCCTCGGGC	CTGAGCCCTC	GGATCGAGAT	CACTCCGTCC	CACGAACTGA	
TCCAGGCAGT	GGGGCCCCCTC	CGCATGAGAG	ACGCGGGCCT	CCTGGTGGAG	240
CAGCCCCCCC	TGGCCGGGGT	GGCCGCCAGC	CCGAGGTTCA	CCCTGCCCGT	
GCCCCGGCTTC	GAGGGCTACC	GCCAGCCGCT	TTGCTTGAGC	CCCGCTAGCA	340
GCGGCTCCTC	TGCCAGCTTC	ATTTCTGACA	CCTTCTCCCC	CTACACCTGC	
CCCTGCGTCT	CGCCCAATAA	CGGCGGGCCC	GACGACCTGT	GTCCGCAGTT	440
TCAAAACATC	CCTGCTCATT	ATTCCCCAG	AACCTCGCCA	ATAATGTCAC	
CTCGAACCAAG	C-TCGCCGAG	GACAGCTGCC	TGGGCCGCCA	CTCGCCCGTG	540
CCCCGTCCGG	CCTCCCGCTC	CTCATCGCCT	GGTGCCAAGC	GGAGGCATTC	
GTGCGCCGAG	GCCTTGGTTG	CCCTGCCGCC	CGGAGCCTCA	CCCCAGCGCT	640
CCCGGAGCCC	CTCGCCGCAG	CCCTCATCTC	ACGTGGCACC	CCAGGACAC	
GGCTCCCCGG	CTGGGTACCC	CCCTGTGGCT	GGCTCTGCCG	TGATCATGGA	740
TGCCCTGAAC	AGCCTCGCCA	CGGACTCGCC	TTGTGG-ATC	CCCCCCAAAGA	
TGTGGAAGAC	CAGCCCTGAC	CCCTCGCCGG	TGTCTCGCGC	CCCATCCAAG	840
GC-GGCCTGC	CTCGCCACAT	CTACCCGGCC	GTGGAGTTCC	TGGGGC--TG	
CGAGCAGGGC	GAGAGGAGAA	ACTCGGCTCC	AGAATCCATC	CTGCTGGTTC	940
CGCCCACCTG	-CCCAAGCCG	CTGGTGCCTG	CCATTCCCAT	CTCGACGATC	
CCATGAGCTC	GATCCCTCCC	T-CACTTGAG	TGGCCGCTGT	CCAGTCAGTC	1040
ATCGCGTTAC	GAGCTGCCGA	TCGAGGTGCA	GC (SEQ ID NO:11)		

FIG. 17

... AYPDDVLDYGLKPYSPLASLSGEPPGRFGEPPDRVGPQKFLSAAKPAG
ASGLSPRIEITPSHELIQAVGPLRMRDAGLLVEQPPLAGVAASPRFTLPV
PGFEGYRQPLCLSPASSGSSASFISDTFSPTYTCPCVSPNNGGPDDLCPQF
QNIPAHYSRTPIMSPRTSLAEDSCLGRHSPVPRPASRSSSPGAKRRHS
CAEALVALPPGASPQRSRSPSPQPSSHVAPQDHGSPAGYPPVAGSAVIMD
ALNSLATDSPCGIPPKMWKTSPDPSPVSRAPS KAGLPRHIYPAVEFLGPC
EQGERRNSAPESILLVPPTWPKPLVPAIPISTIP*ARSLPPLWEPLSSQS
SRYELRIEVQ ... (SEQ ID NO: 12)

FIG. 18

		15/21			50
m	GCGGCTCCTC	TGCCAGCTTC	ATTTCTGACA	CCTTC ₁₅ CCC	CTACACCTCG
h	-----	-----	-----	-----	-----GC
					100
m	CCCTGCGTCT	CACCCAATAA	CGCCGGGCC	GACGACCTGT	GTCCCCAGTT
h	-----	-G-----	--G-----	-----	-----G-----
					150
m	TCAAAACATC	CCTGCTCATT	ATTCCCCCAG	AACCTCTCCA	ATAATGTCAC
h	-----	-----	-----	-----G--	-----
					200
m	CTCGAACCAAG	CCTCGCCGAG	GACAGCTGCC	TGGGCCGACA	CTCGCCCGTG
h	-----	..-----	-----	-----C--	-----
					250
m	CCCCGTCCGG	CATCCCCTC	CTCCTCACCC	GGTGCCAAGC	GGAGGCATTC
h	-----	-C-----	--A--G--T	-----	-----
					300
m	GTGCGCAGAG	GCTTTGGTTG	CTCCTCTGCC	CGCAGCCTCA	CCCCAGCGCT
h	-----C--	--C-----	-C-TG-C--	--G-----	-----
					350
m	CCCGGAGCCC	CTCGCCACAG	CCCTCGCCTC	ACGTGGCACC	GCAGGACGAC
h	-----	-----G--	-----AT--	-----	C-----C--
					400
m	AGCATCCCCG	CTGGGTACCC	CCCCACGGCC	GGCTCTGCTG	TTCTCATGGA
h	G--TC---G-	-----	--TGT---T	-----C-	-GA-----
					450
m	TGCCCTCAAC	ACCCTGGCCA	CCGACTCGCC	CTGCGGGATC	CCCTCCAAGA
h	-----G--	-G---C---	-G-----	T---T---.	---C-----
					500
m	TATGGAAGAC	CAGTGCTGAC	CCGACGCC	TGTCCACCGC	TCCGTCCAAG

FIG. 19-1

h -G----- C----- CT----G- TCG--- C---A-----
m GCTGGCCTGG CCCGCCACAT CTACCCCTACT GTGGAGTTCC TGGGGCCATG 550
h --.-----C -T----- -----GG-C ----- .---
m TGAGCAGGAG GAGAGGAGGA ATTCCGCTCC AGAGTCCATC CTGCTGGTAC 600
h C-----GC -----A- -C--G---- A----- -----T-
m CACCTACTTG GCCCAAGCAG TTGGTGCCGG CCATTCCCAT CTGCAGCATC 650
h -G--C----- .-----C- C-----T- ----- --CG-CG---
m CCTGTGACTG CATCCCTCCC ACCACTCGAG TGGCCACTCT CCAATCAGTC 700
h --ATGAG--C G----- T.----T--- -----G--G- ---G-----
m GGGCTCCTAT GAGCTACGGA TTGAGGTCCA AC (SEQ ID NO:8)
h ATCGCGT--C -----G---- -C-----G-- G- (SEQ ID NO:22)

FIG. 19-2

1 ggatgacqCA GCOACTTCAG AAAGCTGGGT TGGGACAGAA AGGTATATAG AGAGAAAATT ...
(SEQ ID NO:13)
2 ggatgacqAG TTGATAGACA CACACCTTAG CTGGATACAA AACATATTAT GA
(SEQ ID NO:14)
3 ggatgacqTT AATGAAATCA TCAGGAAGGA GTTTTCAGGA CCTCCCTCCC GAAATCAGAC CTAG
(SEQ ID NO:15)

The splice site is after the first nucleotide in the third codon shown.

gat gac gCA GCC ACT TCA GAA AGC TGG GTT GGG ACA GAA AGG TAT ATA ...
D D A A T S E S W V G T E R Y I ...
(SEQ ID NO:16)

gat gac gAG TTG ATA GAC ACA CAC CTT AGC TGG ATA CAA AAC ATA TTA TGA
D D E L I D T H L S W I Q N I L *
(SEQ ID NO:17)

gat gac gTT AAT GAA ATC ATC AGG AAG GAG TTT TCA GGA CCT CCC TCC CGA AAT CAG
D D V N E I I R K E F S G P P S R N Q
ACC TAG
T *
(SEQ ID NO:18)

FIG. 20

FIG. 21

AGCAGGAAGC TCGGCCGCCC GTGCCGCCG CCGCTCAGCT TCCCCGGCG CGTCCAGGAC
CCGCTGCCGCG AGGCGCGCCG TCCCCGGACC CGGCCTGCCT CCCTACGAGG AAAGGGACCC
CGCCGCTCGA GCCGCCCTCG CCAGCCCCAC TGCAGGGGT CCCAGAGCCA GCCGCCGCC
CCCTCGCCCC CGGCCCCGCA GCCTTCCCG CCTGCCTGCC ATGAACGCC CCGAGCGGCA
GCCCCAACCC GACGGGGGG ACGCCCCAGG CCACGAGCCT GGGGGCAGCC CCCAAGACGA
GCCTTGACTTC TCCATCCTCT TCGACTATGA GTATTTGAAT CCGAACGAAG AAGAGCCGAA
TGCACATAAG GTCGCCAGCC CACCCCTCCGG ACCCGCATAC CCCGATGATG TCCTGGACTA
TGGCCTCAAG CCATACAGCC CCCTTGCTAG TCTCTCTGGC GAGCCCCCG GCCGATTGG
AGAGCCGGAT AGGGTAGGGC CGCAGAAGTT TCTGAGCGCG GCCAAGCCAG CAGGGGGCCTC
GGGCCTGAGC CCTCGGATCG AGATCACTCC GTCCCCACGAA CTGATCCAGG CAGTGGGGCC
CCTCCGCATG AGAGACGCGG GCCTCCCTGGT GGAGCAGCCG CCCCTGGCCG GGGTGGCCGC
CAGCCCCAGG TTCACCCCTGC CCCGTCCCCGG CTTCGAGGGC TACCGCGAGC CGCTTGCTT
GAGCCCCGCT AGCAGCGGCT CCTCTGCCAG TTTCATTTCT GACACCTTCT CCCCTACAC
CTCGCCCTGC GTCTGCCCA ATAACGGCGG GCCCAGACGAC CTGTGTCCGC AGTTTCAAAA
CATCCCTGCT CATTATTCCTT CCAGAACCTC GCCAATAATG TCACCTCGAA CCAGCCTCGC
CGAGGACAGC TGCCCTGGGCC GCCACTCGCC CGTGGCCCGT CCGGCCTCCC GTCCTCATC
GCCCTGGTGCC AAGCGGAGGC ATTCTGCGC CGAGGCCTTG GTTGCCTGC CGCCCGGAGC
CTCACCCCCAG CGCTCCCGGA GCCCCCTGCC GCAGCCCTCA TCTCAGTGG CACCCCCAGGA
CCACGGCTCC CGGGCTGGGT ACCCCCCCTGT GGCTGGCTCT GCGGTGATCA TGGATGCCCT
GAACAGCCTC GCCACGGACT CGCCCTGTGG GATCCCCCC AAGATGTGGA AGACCAGCCC
TGACCCCTCG CGGGTGTCTG CGGCCCCATC CAAGGGGGC CTGCCTCGCC ACATCTACCC
GGCCGTGGAG TTCCCTGGGGC CCTGGGAGCA GGGCGAGAGG AGAAAATCGG CTCCAGAATC
CATCCCTGCTG GTTCCGCCA CTTGGCCCAA ACCGCTGGTG CCTGCCATTC CCATCTGCCAG
CATCCCAGTG ACTGCATCCC TCCCTCCACT TGAGTGGCCG CTGTCCAGTC AGTCAGGCTC
TTACGAGCTG CGGATCGAGG TGCAGCCTCG TGCC

(SEQ ID NO:19)

1 GCGGCTCCTC TGCCAGCTTC ATTTCTGACA CCTTCTCCCC CTACACCTCG
51 CCCTGCCTCT CACCCAATAA CGCCGGGCC GACGACCTGT GTCCCCAGTT
101 TCAAAACATC CCTGCTCATT ATTCCCCAG AACCTCTCCA ATAATGTCAC
151 CTCGAACCAG CCTCGCCGAG GACAGCTGCC TGGGCCGACA CTCGCCGTG
201 CCCCGTCCGG CATCCCGCTC CTCCTCACCC GGTGCCAAGC GGAGGCATTC
251 GTGCGCAGAG GCTTTGGTTG CTCCCTTGCC CGCAGCCTCA CCCCAGCGCT
301 CCCGGAGCCC CTCGCCACAG CCCTGCCTC ACGTGGCACC GCAGGACGAC
351 AGCATCCCCG CTGGGTACCC CCCCACGGCC GGCTCTGCTG TTCTCATGGA
401 TGCCCTCAAC ACCCTGGCCA CCGACTCGCC CTGCGGGATC CCCTCCAAGA
451 TATGGAAGAC CAGTCCTGAC CCGACGCCTG TGTCCACCGC TCCGTCCAAG
501 GCTGGCCTGG CCCGCCACAT CTACCTACT GTGGAGTTCC TGGGGCCATG
551 TGAGCAGGAG GAGAGGAGGA ATTCCGCTCC AGAGTCCATC CTGCTGGTAC
601 CACCTACTTG GCCCAAGCAG TTGGTGCCGG CCATTCCCAT CTGCAGCATE
651 CCTGTGACTG CATCCCTCCC ACCACTCGAG TGGCCACTCT CCAATCAGTC
701 GGGCTCCTAT GAGCTACGGA TTGAGGTCCA ACCCAAGCCC CATCACCGGG
751 CCCACTATGA GACGGAGGGC AGCCGTGGCG CTGTCAAAGC CCCAACAGGA
801 GGACACCCCTG TGGTGCAGCT CCACGGCTAC ATGGAGAACCA AGCCTCTGGG
851 GCTTCAGATC TTCATTGGGA CAGCAGATGA GAGGATCCTT AAGCCGCACG
901 CCTTCTACCA AGTACACAGG ATCACTGGGA AAACGGTCAC CACCACGAGC
951 TATGAGAAGA TCGTAGGCAA CACCAAGGTC CTGGAGATCC CCCTGGAGCC
1001 AAAGAACAAAC ATGAGAGCCA CCATCGACTG TGCAGGCATC CTGAAGCTCC
1051 GAAACGCTGA CATCGAGCTG CGGAAGGGCG AGACGGACAT CGGCAGGAAG
1101 AACACGCGTG TGGCCTGGT GTTCCCGGTG CACGTCCCAG AGCCCAGTGG
1151 GCGCATCGTC TCCCTGCAGG CTGGTCCAA CCCCACATCGAG TGCTCTCAGC
1201 GCTCTGCCCA CGAGCTGCC ATGGTGGAGA GACAAGACAT GGACAGCTGC
1251 CTGGTCTACG GGGGCCAGCA GATGATCCTC ACGGGCCAGA ACTTCACAGC
1301 GGAGTCCAAG GTTGTGTTCA TGGAGAACAC TACAGATGGG CAGCAGATTT

FIG. 22-1

20/21

1351 GGGAGATGGA AGTACGGTG GATAAAGACA AGAGCCAG TAACATGCTT
1401 TTTGTTGAGA TCCCCGAGTA TCGGAACAAG CACATCCGCG TGCCCGTGAA
1451 AGTCAACTTC TACGTCATCA ACGGAAAGAG GAAACGAAGT CAGCCACAGC
1501 ACTTTACCTA CCACCCCAGTC CCTGCCATCA AGACAGAGCC CAGCGATGAG
1551 TATGAACCAT CTTTGATCTG CAGCCCCGCC CATGGAGGCC TGGGGAGCCA
1601 GCCATATTAC CCACAGCACC CAATGCTGGC CGAGTCCCCC TCCTGCCTTG
1651 TGGCTACCAT GGCCCCCTGC CAACAGTTCC GCTCGGGGCT CTCATCCCCC
1701 GATGCTCGCT ACCAACAGCA GAGCCCCGCA GCTGCCCTCT ACCAGAGAAG
1751 CAAGAGCCTG AGTCCCGGCC TGCTGGGCTA CCAGCAGCCG TCCCTCCTGG
1801 CAGCACCCCTT GGGTCTGGCT GATGCCACC GCTCTGTGCT GGTGCATGCT
1851 GGTTCTCAGG GGCAGGGGCA GGGCTCCACC CTCCGACACA CATCCTCGGC
1901 CAGCCAGCAG GCCTCACCCG TGATCCACTA CTCACCCACC AACCAAGCAGC
1951 TTCGGGGTGG GGGTCACCAG GAGTTCCAGC ATATCATGTA CTGTGAAAAC
2001 TTCGGCCCCA GCTCTGCCAG GCCTGGCCCG CCTCCCATCA ACCAAGGTCA
2051 GAGGCTGAGC CCGGGCGCCT ACCCCACAGT CATCCAACAA CAGACTGCC
2101 CGAGCCAAAG AGCTGCCAAA AACGGACCCA GTGACCAGAA GGAAGCTCTG
2151 CCCACGGGAG TGACCGTCAA ACAGGAACAG AACCTGGACC AGACCTACCT
2201 GGATGACGCA GCCACTTCAG AAAGCTGGGT TGGGACAGAA AGGTATATAG
2251 AGAGAAAATT TTGGAAGAAG ACCCTTGTGC AGCCTGGCT CCTGCCCTCA
2301 TTTTACTTC TTGGCTCCCT GTCTGCTGGA CCAAGGTAC AGACACCATC
2351 AGAAAGAAAG CCCATAGAGG AAGACGTGCC CTTGAGTTGC AGCCAGATAG
2401 CCTGGTGGTGC TCAGCATCCC TTGGGGACCT GCCCTGTCCCT GCCAGGGCCT
2451 TTAGCTGTAG AGTGGTGGGA AGGGCAGCTC GGGCGTGGC TGGAGCCAAT
2501 TCCCTGGGCT CCAGACAGTG CCGGCAGCCT CCATGAGGTG GACAGTGTAG
2551 GCCTGGCGGG AGTGGTCGGA ATGGTTCTGC TCACTCTTAT GCACCACTTC
2601 TCCATGGATC AGAACCAAGAC CCCCTCTCCT CACTGGCAAA GGCACAAAGA
2651 CGTTGCTAGC CCAGGCTGGA TCTGA (SEQ ID NO:21)

FIG. 22-2

ATGGGCTCAT CAACTTCATC AAGCAGCAGC GCGAGGCCAG AGTCCAATAA
ACTCGTGCTC ATCTGCAGCC TCCTCTGTGA CTCCCCTTCT CTTCTCGTCC
CTCCTCCCCG GAGC (SEQ ID NO: 20)

FIG. 23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/00545

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.2, 21, 69.1, 240.2, 252.3, 320.1; 436/501, 513; 530/358, 388.23; 536/23.5; 930/130

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, BIOSIS, MEDLINE, EMBASE

search terms: NF-AT, nuclear factor, T cells, calcineuron, assay, Fos, Jun

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	Journal of Experimental Medicine, Volume 178, issued November 1993, M. Woodrow et al., "p21ras and calcineurin synergize to regulate the nuclear factor of activated T cells", pages 1517-1521, especially abstract, pages 1520-1521.	5-9, 17, 21-32, 34, 35
X ,P Y	Science, Volume 262, issued 29 October 1993, P.G. McCaffrey et al., "Isolation of the cyclosporin-sensitive T cell transcription factor NFATp", pages 750-754, see entire document.	1-15, 19, 20, 22-32, 34, 35 16-18, 21, 33

 Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 APRIL 1994

Date of mailing of the international search report

APR 25 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DIAN C. JACOBSON

Telephone No. (703) 308-0196

Jill Warden for

INTERNATIONAL SEARCH REPORT

In: International application No.
PCT/US94/00545

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	The Journal of Biological Chemistry, Volume 268, No. 19, issued 05 July 1993, N.R. Yaseen et al., "Comparative analysis of NFAT (Nuclear factor of activated T cells) complex in human T and B lymphocytes", pages 14285-14293, see entire document.	1-4, 10-12, 19-20
X	The Journal of Biological Chemistry, Volume 268, No. 5, issued 05 February 1993, P.G. McCaffrey et al., "NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs", pages 3747-3752, see entire document.	1-4, 10-12
Y	Proceedings of National Academy of Science, Volume 75, No. 6, issued June 1978, S. Broome et al., "Immunological screening method to detect specific translation products", pages 2746-2749, see entire document.	17, 21
X	Nature, Volume 356, issued 30 April 1992, J. Jain et al., "Nuclear factor of activated T cells contains Fos and Jun", pages 801-804, see entire document.	15
Y		1-4, 10-12 5-9, 13-35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/00545

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (5):

C07K 13/00, 15/28; C12N 1/21, 5/10, 15/10, 15/11, 15/19, 15/64; C12Q 1/00

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

435/6, 7.2, 21, 69.1, 240.2, 252.3, 320.1; 436/501, 513; 530/358, 388.23; 536/23.5; 930/130